

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Refractive Outcomes After Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) Versus Laser Photocoagulation for Retinopathy of Prematurity: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042384
Article Type:	Original research
Date Submitted by the Author:	04-Jul-2020
Complete List of Authors:	Kong, Qihang; Jinan University, Ophthalmology Ming, Wai-kit; Jinan University, Department of Public Health and Preventive Medicine; Hong Kong University, Li Ka Shing Faculty of Medicine Mi, xue-song; Jinan University, Ophthalmology
Keywords:	Paediatric ophthalmology < OPHTHALMOLOGY, Medical ophthalmology < OPHTHALMOLOGY, Paediatric surgery < SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Refractive Outcomes After Intravitreal Anti-vascular Endothelial Growth**
5
6 **Factor (Anti-VEGF) Versus Laser Photocoagulation for Retinopathy of**
7
8
9 **Prematurity: A meta-analysis**
10

11 Qi-Hang Kong, MBBS¹ Wai-kit Ming, MD, PhD, MPH^{2,3}, Xue-Song Mi, MD, PhD¹

12
13
14 1.Department of Ophthalmology, the First Affiliated Hospital of Jinan University, Guangzhou,
15 Guangdong Province, China.

16
17
18 2.Department of Public Health and Preventive Medicine, School of Medicine, Jinan University,
19 Guangzhou, China

20
21
22 3.Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
23

24 **Corresponding Author:**

25
26
27 Xue-Song Mi, MD, PhD, Department of Ophthalmology, the First Affiliated
28 Hospital of Jinan University, Guangzhou, Guangdong Province, China.

29
30
31 **Phone number:**+86 17665185740

32
33
34 **E-mail address:**kqh211@stu2018.jnu.edu.cn

35
36
37 Wai-kit Ming, MD, PhD, MPH, 1.Department of Public Health and Preventive
38 Medicine, School of Medicine, Jinan University, Guangzhou, China, 2.Li Ka
39 Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
40
41
42
43

44
45 **Phone number:**+86 15625012076

46
47 **E-mail address:** 2981365101@qq.com

48
49
50 **Total number of tables plus figures:**6

51
52 **Funding:** The research did not receive any specific funding from any institution.

53
54
55 **Conflicts of interest:** The author declares that the publication of this paper has
56 no financial support or conflict of interest.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Retinopathy of Prematurity; Anti-VEGF; Refractive Errors; myopia

For peer review only

1 Abstract

2 **Objective:** To evaluate the effect of intraocular injection of anti-vascular
3 endothelial growth factor (anti-VEGF) on the refractive status of premature
4 infants with retinopathy.

5 **Design:** Systematic review and meta-analysis to evaluate the refractive status
6 of anti-VEGF in Retinopathy of prematurity (ROP) children.

7 **Methods:** We searched four databases through January 2020, including
8 PubMed, Web of Science, EMBASE, and ClinicalTrials.gov website, to identify
9 randomized, controlled, and observational studies that investigated refractive
10 errors between anti-VEGF and laser therapy. We used a random-effects model
11 to pool outcomes. The outcome measures were spherical equivalent (SE), axial
12 length (AL), anterior chamber depth (ACD), and lens thickness (LT).

13 **Results:** Thirteen studies with 1850 eyes were assessed, of which 914 eyes
14 were in anti-VEGF group, while 936 were in control (laser) group. Children who
15 received anti-VEGF treatment had less myopia than those who received laser
16 therapy (Mean Difference 1.80, 95% CI: 0.97 to 2.63, $P < 0.0001$, $I^2 = 78\%$).
17 axial length (Mean Difference -0.04, 95% CI: -0.30 to 0.21, $P = 0.75$, $I^2 = 30\%$),
18 anterior chamber depth (Mean Difference 0.19, 95% CI: -0.14 to 0.52, $P = 0.25$, I^2
19 = 85%) and lens thickness (Mean Difference 0.06; 95% CI: -0.56 to 0.67, P
20 = 0.85, $I^2 = 97\%$) had no statistical significance on anti-VEGF therapy for
21 retinopathy of prematurity.

22 **Conclusions:** Our meta-analysis indicates that anti-VEGF therapy reduces

1 myopia compared to laser therapy. However, the number of published articles
2 on refractive error in ROP is limited. Hence, it is necessary to conduct high-
3 quality and powerful randomized controlled trials in the future.

4 **PROSPERO registration number:** CRD42020160673

5 **Strengths and limitations of this study**

6 Our meta-analysis adhered to the methodology recommendations of the
7 Cochrane handbook. we conducted a thorough literature search.

8 The article has a formal registered review protocol on PROSPERO, and our
9 article was conducted and reported with rigorous methods following the
10 PRISMA.

11 We included other parameters that may affect the refractive errors of ROP
12 children, such as ACD, LT, AL, in our meta-analysis.

13 Most of the literature we included are observational studies, and only 2 articles
14 are RCTs, if more RCTs are included, we can draw more reliable conclusions.

15 **Introduction**

16 Retinopathy of prematurity (ROP) is a common cause of blindness in developed
17 countries and is increasingly prevalent in developing countries.¹ Characterized
18 by retinal ischemia, aberrant angiogenesis, fibrovascular proliferation, and
19 progressive vitreoretinal traction, ROP accounts for 14% of childhood blindness
20 within the United States and greater than 20% in developing countries.²

21 Retinopathy of prematurity is a unique retinal vascular proliferative disease
22 occurring in premature infants and low birth weight infants.³ Normally, retinal

1
2
3
4 1 vascularization occurs around 12 weeks and is completed in 36 to 40 weeks of
5
6 2 gestation. Because premature infants leave the uterus prematurely, the retinal
7
8 3 system is immature. The loss of maternal interaction environment and exposure
9
10 4 to high oxygen in premature infants can lead to the cessation of retinal
11
12 5 vascularization, damage to capillary endothelium, hypoxia of the retinal blood
13
14 6 vessels, stimulation of fibrovascular tissue proliferation, and finally may lead to
15
16 7 traction retinal detachment.⁴

17
18 8 In the past, laser photocoagulation has been the main treatment for ROP. In
19
20 9 spite of the effectivity and safety provided by laser photocoagulation, a few
21
22 10 defects still remain in this kind of treatment, such as high myopia, visual field
23
24 11 loss, and retinal destruction. With the intensive study of ROP, it was found that
25
26 12 the levels of VEGF in the vitreous of eyes at stage 4 ROP have greatly
27
28 13 increased.⁵ In a normally developing retina, VEGF promotes the development
29
30 14 of blood vessels from the optic nerve to the periphery, but in preterm infants,
31
32 15 the overexpression of VEGF leads to abnormal vascular proliferation.⁶
33
34 16 Therefore, researchers have sought to use anti-VEGF to treat ROP. Many
35
36 17 studies have shown that intravitreal injection of anti-VEGF drugs may be an
37
38 18 effective intervention measure when used in the clinical treatment of ROP.^{7, 8 9}
39
40 19 However, intravitreal injection of anti-VEGF drugs for the treatment of ROP is
41
42 20 a relatively short-term clinical application, and its long-term complications are
43
44 21 unclear. There is still controversy as to whether or not postoperative refractive
45
46 22 errors can be caused. Kang et al's study¹⁰ showed that anti-VEGF drugs do
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 not cause refractive error after ROP treatment, while Kabatas et al¹¹ found
5
6 2 that intravitreal injection of anti-VEGF drugs treatment is the same as laser
7
8
9 3 photocoagulation treatment, both can cause refractive errors, and there is no
10
11 4 statistical difference between the two groups.

12
13
14 5 With the increasing clinical application of anti-VEGF drugs, it is urgent to know
15
16 6 whether these drugs can also cause refractive errors in children with ROP.
17
18
19 7 Hence, the purpose of our meta-analysis is to evaluate the effect of anti-VEGF
20
21 8 drugs on the refractive status of ROP compared to laser treatment and to further
22
23 9 verify the clinical safety of anti-VEGF drugs. The outcome measures are
24
25 10 spherical equivalent (SE), axial length (AL), anterior chamber depth (ACD)
26
27 11 lens thickness (LT).

12 **Methods**

13 We report our study according to the meta-analyses of PRISMA guidelines.¹²
14 Our study has been registered on PROSPERO (number CRD42020160673).

15 **Data sources and search strategy.**

16 From inception to January 2020, We searched PubMed, Web of Science,
17 EMBASE, and ClinicalTrials.gov website using keywords and medical subject
18 headings. Only studies published in the English language were considered for
19 inclusion. Additionally, we searched the reference lists of included studies to
20 prevent missing some potentially available articles. Search terms included
21 "Retinopathy of Prematurity," "Prematurity Retinopathy," "Retrolental

1 Fibroplasia,” “Fibroplasia, Retrolental,” “ROP,” “Anti-VEGF,” “Bevacizumab,”
2 “Avastin,” “Lucentis,” “Ranibizumab,” “aflibercept,” “Anti-vascular endothelial
3 growth factor,” “Mvasi,” and “Refractive Errors,” “Disorders, Refractive,” and
4 “Ametropias.” The search strategy is detailed in the S1 strategy(online
5 supplementary material).

6 **Study selection and eligibility criteria.**

7 Each study was independently screened by two authors (QHK and MXS).
8 Discrepancies between the screenings of the two reviewers were solved
9 through discussion with the third author (WM). The inclusion criteria in our
10 article were following: 1) Study population: Children who have been clearly
11 diagnosed with retinopathy of prematurity; 2) Intervention group: Intraocular
12 injection of anti-VEGF, including any anti-VEGF drug that can be used in
13 children with ROP ;3) Control group: Laser treatment of the eye included retinal
14 argon laser and diode laser.; 4)Outcome of interest: The refractive status of
15 treated ROP children, including spherical equivalent (SE) and some ocular
16 biometric structural features, such as axial length (AL), anterior chamber
17 depth (ACD), and lens thickness (LT); 5) Study design: Randomized controlled
18 study and observational study. We excluded children with stage 4 or 5 ROP or
19 other eye diseases (such as congenital cataract or glaucoma) prior to treatment.

20 **Data extraction and quality assessment.**

21 The following information was extracted from the included studies: the name of

1 the first author, publication year, sample size, number of eyes, GA (gestational
2 age), BW (birth weight), follow-up time, the type of anti-VEGF, anti-VEGF dose,
3 and result data (SE, AL, ACD, LT). When two anti-VEGF drugs were included
4 in the literature, we extracted the data separately and compared the data with
5 the control group. We entered the extracted data into an Excel file. Two of the
6 authors (QHK and MXS) assessed the quality of studies by the Newcastle-
7 Ottawa Scales.¹³ The NOS consists of 4 items for subject selection (4 points),
8 1 item for comparability between groups (2 points), and 3 items for outcome
9 measurement (3 points). Studies of different quality are awarded different
10 scores, with a maximum of 9, a moderate quality of 4–6, and a high quality of
11 7–9.¹⁴

12 **Statistical analysis.**

13 The weighted mean differences (WMDs) with 95% CIs of continuous variables
14 were calculated. Meanwhile, heterogeneity between included studies was
15 discussed using the I^2 statistic. I^2 values of 25% to 50%, 50% to 75%, 75% to
16 100% were considered low heterogeneity, moderate heterogeneity and high
17 heterogeneity.¹⁵ Because of the potential for heterogeneity between studies,
18 we used a more conservative version of the random-effects model. To evaluate
19 potential publication bias, we used a visual funnel plot. If the funnel plot was
20 asymmetric, there was publication bias. Meanwhile, the Egger test was also
21 used to provide an accurate assessment, whereby if $p < 0.05$, it was considered

1 statistically significant, i.e. there was some degree of publication bias. All
2 statistical analyses were performed using RevMan software (version 5.3,
3 Nordic Cochrane Centre) and Stata software (version 12.0, Stata Corp LP).

4 **Results**

5 **Literature search.**

6 The initial search identified 121 records. After screening the titles and abstracts,
7 31 potentially eligible studies were assessed for inclusion. After reading the full
8 text in our meta-analysis, a total of 13 studies were finally included. The study
9 selection diagram is presented in **Figure 1**.

10 A total of 13 studies were selected, including 2 RCTs^{16, 17} and 11 observational
11 studies^{11, 18-27}. According to the scoring criteria of the Newcastle-Ottawa scale,
12 eleven studies were evaluated as high quality, and two studies were evaluated
13 as moderate-quality. The median NOS score of the included studies was 8
14 (range of 6-8). These studies were published between 2013 and 2019. The
15 sample size of the studies ranged from 12 to 397, with a total of 1850 eyes
16 comprising 914 in the anti-VEGF group and 936 in the control group. In the anti-
17 VEGF group, anti-VEGF drugs were bevacizumab and ranibizumab. Only one
18 of the above-mentioned drugs was used in 12 pieces of literature and two drugs
19 were used in one literature. The dosage of anti-VEGF drugs also varied in all
20 the included literature. The minimum dose was 0.2mg, the maximum dose was
21 1.25mg, and the majority of the literature used 0.625 mg. After injection of anti-
22 VEGF drugs, ROP children were followed regularly for more than 6 months,

1 ranging from 9 months to 5 years. Among the thirteen studies included here, all
2 reported spherical equivalent, four reported axial length, three reported anterior
3 chamber depth, and two reported lens thickness. We presented the main
4 information within the included studies in our meta-analysis (**Table 1**)

For peer review only

Table 1: Main Characteristics of Studies Included in the Meta-analysis

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Harder et al ¹⁸	Germany	Anti-VEGF	12/23	25.20 ± 1.60	622.00 ± 153.00	12	bevacizumab	0.375 or 0.625	7
		laser	13/26	25.30± 1.80	717.00 ± 197.00				
Hwang et al ¹⁹	American	Anti-VEGF	11/22	NA	668.10 ± 127.30	21.7	bevacizumab	0.625	8
		laser	17/32		701.40 ± 118.80	32.5			
Kabataş et al ¹¹ *	Turkey	Anti-VEGF	12/24	26.10 ± 2.27	841.00 ± 235.00	18	bevacizumab	0.625	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kabataş et al ¹¹ *	Turkey	Anti-VEGF	6/12	26.00 ± 1.26	840.00 ± 177.00	18	ranibizumab	0.25	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kuo et al ²⁰	Taiwan	Anti-VEGF	15/15	27.33 ± 2.94	1,079.67 ± 357.48	3 years	bevacizumab	0.5	7
		laser	14/14	27.43± 2.93	1,006.79 ± 327.65	of age			
Kang et al ²¹	Korea	Anti-VEGF	12/22	27.40 ± 2.00	983.20 ± 265.60	4 years	bevacizumab	0.625	7
		laser	15/30	34.00 ± 2.90	961.00 ± 286.50	of age			
Isaac et al ²²	Canada	Anti-VEGF	13/23	25.20 ± 1.40	722.00 ± 131.00	16.00±6.00	bevacizumab	0.625	8
		laser	12/22	25.00 ± 1.10	674.00 ± 175.00	6.00±3.00			
Vujanović et al ²³	Serbia	Anti-VEGF	21/42	29.00 ± 4.00	1,175.00 ± 425.00	9	bevacizumab	0.625	8
		laser	45/90	30.00 ± 4.00	1,200.00 ± 500.00				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1 (continued)

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Gunay et al ²⁴ *	Turkey	Anti-VEGF	55/107	27.31 ± 2.18	1005.29 ± 411.19	19.40±6.43	bevacizumab	0.625	8
		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Gunay et al ²⁴ *	Turkey	Anti-VEGF	22/44	27.95 ± 2.90	1195.90 ± 466.98	18.96±4.79	ranibizumab	0.25	8
		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Chen et al ²⁵	Taiwan	Anti-VEGF	13/25	26.46 ± 1.51	862.54 ± 197.65	NA	bevacizumab	0.625	7
		laser	12/22	25.50 ± 1.24	815.83 ± 151.07				
Lee et al ²⁶	Taiwan	Anti-VEGF	17/33	26.60 ± 1.60	874.10 ± 228.70	> 48	bevacizumab	0.625	6
		laser	13/24	26.60 ± 2.50	803.10 ± 144.90				
Roohipoor et al ²⁷	Iran	Anti-VEGF	NA/397	27.8	1146	> 12	bevacizumab	0.625	8
		laser	NA/190						
Geloneck et al ^{16*}	American	Anti-VEGF	56/110	24.3	625	2.5 years of age	bevacizumab	0.625	8
		laser	53/101						
O'Keeffe et al ^{17*}	Irish	Anti-VEGF laser	15/15 15/15	25±1.25	780±135	60	bevacizumab	1.25	6

*: RCT, Randomized Controlled Trial; NOS: Newcastle-Ottawa Scale; NA: not applicable; GA: gestational age; BW: birth weight;

* : There are two types of Anti-VEGF drugs included in the literature, so the details are listed separately

1 **Main outcomes**

2 **Spherical equivalent (SE).** Thirteen studies reported the spherical equivalent
3 (SE), with 914 eyes in the anti-VEGF group versus 936 eyes in the control group.
4 **(Figure 2).** The anti-VEGF group had a higher spherical equivalent (MD 1.80,
5 95% CI: 0.97 to 2.63). compared to the control group, with high heterogeneity
6 ($I^2 = 78\%$). The findings of the subgroup analysis for the spherical equivalent
7 according to type of article included are summarized in **Figure 3.**

8 **Axial length (AL).** Four studies^{23, 25, 26} reported the axial length (AL), with 251
9 eyes in the anti-VEGF group versus 362 eyes in the control group. **(Figure 4).**
10 There was no statistical difference between the groups (MD -0.04, 95% CI: -
11 0.30 to 0.21), with low heterogeneity ($I^2 = 30\%$).

12 **Anterior chamber depth (ACD).** Three studies^{23, 25, 26} reported anterior
13 chamber depth (ACD) in ROP children with or without anti-VEGF. Our study
14 found no difference between anti-VEGF and the control group (MD 0.19; 95%
15 CI: -0.14 to 0.52, $I^2 = 85\%$). **(Figure 5)** There was a high heterogeneity ($I^2 =$
16 85%). However, in sensitivity analysis by excluding Vujanović's study, moderate
17 heterogeneity can be observed (MD 0.39; 95% CI: -0.06 to 0.84, $I^2 = 64\%$).

18 **Lens thickness (LT).** Two studies^{23, 25} assessed lens thickness (LT) on anti-
19 VEGF group and a control group. The difference of LT between anti-VEGF and
20 laser group had no significant difference (MD 0.06; 95% CI: -0.56 to 0.67, P
21 $=0.85$), and the I^2 was 97%. (online supplementary material S2 forest plot).

22 **Publication Bias**

1
2
3
4 1 To investigate the publication bias, we made a funnel plot using Stata software.
5
6 2 Through visual examination and statistical calculations, we did not find the
7
8
9 3 existence of any publication bias ($P = 0.401$ by Egger test). (online
10
11
12 4 supplementary material S3 funnel plot)

5 **Discussion**

6 Our meta-analysis identified 13 studies investigating the association between
7
8 the treatment groups and refractive errors for ROP. The analysis of this study
9
10 was based on SE, AL, ACD, and LT. As the results showed, there was a
11
12 statistically significant difference in SE between the two groups. In other words,
13
14 anti-VEGF treatment reduces myopia in ROP children compared to laser
15
16 treatment, and this evidence is consistent in both the comprehensive and
17
18 subgroup analyses. However, no statistical significance was found in other
19
20 variables in our study.

21 A meta-analysis has been published on similar subjects.²⁸ Tan et al.'s meta-
22
23 analysis included a total of 7 articles, including a total of 519 eyes. The anti-
24
25 VEGF drug was limited to bevacizumab. Although the main finding of our meta-
26
27 analysis was consistent with previous meta-analyses, there are some
28
29 differences between them. Firstly, our literature included 13 articles with a total
30
31 of 1850 eyes. Our current article is the latest meta-analysis, which includes
32
33 some recently published literature, and further strengthens the results of the
34
35 previous meta-analysis by increasing the statistical power of the number of
36
37 cases. secondly, We increased the variety of anti-VEGF drugs, not only limited
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 to bevacizumab, but also other commonly used anti-VEGF drugs in clinical
2 practice, such as ranibizumab. This can bring the conclusion closer to clinical
3 reality. Lastly, we added other ocular parameters to investigate the association
4 with refractive errors between anti-VEGF drugs and laser therapy, such as ACD,
5 LT, AL. A previous study has shown that ocular refractive parameters including
6 ACD, LT, AL may be related to myopic adults with ROP,²⁹ but there is no
7 evidence that laser treatment and anti-VEGF treatment have different refractive
8 statuses in ROP children. Therefore, we analyzed the above ocular parameters
9 in laser and anti-VEGF groups. This further increases the evidence that anti-
10 VEGF treatment is safe for ROP children.

11 This is a meta-analysis of 13 papers synthesizing the literature to evaluate the
12 refractive safety of anti-VEGF for children with ROP. Our meta-analysis shows
13 that anti-VEGF treatment has better refractive results compared to laser
14 treatment. As seen in previous studies, anti-VEGF therapy reduces myopic
15 more than the laser treatment in the current study. Describing refractive errors
16 usually use SE in most previously published studies, the spherical equivalent is
17 considered the primary measure of refractive error .so we also used the
18 parameter to explore the differences between the two groups in our article. Kuo
19 et al²⁰ and Issec et al²² reported no statistical difference in refractive error
20 between anti-VEGF and laser groups. However, our meta-analysis found that
21 anti-VEGF therapy reduces myopia and refractive errors more, compared to
22 laser treatment. Two factors may explain the difference. First, both articles

1 utilized a small sample size for their research. Second, the children included
2 had a higher proportion of severe ROP. Therefore, anti-VEGF therapy may be
3 an alternative to laser therapy in reducing refractive error in ROP children. Our
4 subgroup analysis found that anti-VEGF therapy had a better refractive effect
5 than laser therapy, whether in RCTs or in observational studies. Although laser
6 therapy has been considered the first choice of ROP treatment and is well-
7 established in terms of safety and efficacy, the retina is permanently cauterized,
8 resulting in inadequate vascularization and the risk of visual field loss, high
9 myopia, and cataracts. In refraction, there is also an article suggesting that laser
10 treatment may be a risk factor for refractive error in children with ROP³⁰
11 Therefore, when treating ROP, we have to consider the impact of the damage
12 that may result from laser treatment on the ROP children's future refractive
13 status, and it is necessary to find a treatment method that increases both
14 effectiveness and safety. With the in-depth study of the ROP mechanism by
15 researchers, it was found that intraocular injection of anti-VEGF may be a good
16 alternative to laser treatment.²² Intraocular injection of anti-VEGF drugs has the
17 advantage of small trauma, less pain, and easy operation, and it is increasingly
18 used by a wide number of clinicians. Hence, it is essential to clarify the safety
19 of refractive aspect as soon as possible, and our meta-analysis provides good
20 evidence for anti-VEGF drugs in terms of refractive safety. Changes in the
21 biometric structure of the eye, such as ACD, LT, AL corneal curvature and
22 corneal diameter may be related to an increased refractive error in previously

1 published literature.³¹⁻³³ We, therefore, consider the above indicators of ocular
2 biometric structure to be essential when verifying the refractive status of
3 children with ROP. Although previous meta-analyses have reported refractive
4 outcomes after treatment of ROP with anti-VEGF therapy, these meta-analyses
5 have not explored the relationship between refractive outcomes and biometric
6 structure of the eye when comparing anti-VEGF and laser therapy. Hence, our
7 article further investigated these parameters between the two groups. However,
8 our study shows that these parameters have no statistically significant
9 difference when comparing the anti-VEGF and laser group. But there is also
10 much debate about whether anti-VEGF treatment of ROP will cause changes
11 in ocular parameters. Lee et al found that AL did not differ among different
12 treatment groups. Gunay et al³⁴ reported that in children who receive anti-VEGF
13 therapy, the axial length axial might be related to the development of myopia
14 and not related to anterior chamber depth or lens thickness. The BEAT-ROP
15 believes that anti-VEGF treatment may continue the local growth factor
16 expression and signaling pathways, allowing the anterior segment to develop
17 normally¹⁶. The small number of articles that include ocular biometric structure
18 makes it difficult to draw definitive conclusions, so we need more high-quality
19 RCTs to verify the impact of anti-VEGF on the ocular biometric structure in the
20 future. For future research, we believe that we should focus on the following
21 two aspects. Firstly, there is no unified standard for the dose used in the
22 treatment of ROP with anti-VEGF. Most clinical applications used doses are

1
2
3
4 1 half of the adults, but if other doses of anti-VEGF treatment of ROP affect the
5
6 2 result, we do not know, so in the future, a clear plan for the dose of anti-VEGF
7
8
9 3 needs to be proposed. Secondly, there is no clear standard for the follow-up
10
11 4 time of children with ROP. If the follow-up time is too short, the conclusions that
12
13
14 5 may be drawn lack credibility. Therefore, a reasonable plan should be proposed
15
16
17 6 for the follow-up time of children after treatment with anti-VEGF.

18
19 7 The first strength of the article is that our meta-analysis adhered to the
20
21
22 8 methodology recommendations of the Cochrane handbook. we conducted a
23
24
25 9 thorough literature search. Second, the meta-analysis has a formal registered
26
27
28 10 review protocol on PROSPERO, and our article was conducted and reported
29
30
31 11 with rigorous methods following the PRISMA. Third, we included other
32
33
34 12 parameters that may affect the refractive errors of ROP children, such as ACD,
35
36
37 13 LT, AL, in our meta-analysis. Our article further strengthens the evidence of the
38
39
40 14 safety of anti-VEGF drugs in children with ROP. However, our article also has
41
42
43 15 certain limitations. Most of the literature we included are observational studies,
44
45
46 16 and only 2 articles are RCTs, if more RCTs are included, we can draw more
47
48
49 17 reliable conclusions.

18 **Conclusions**

19 In conclusion, the present meta-analysis showed that anti-VEGF therapy
20
21
22 20 reduces myopia more effectively compared to laser treatment. Current
23
24
25 21 evidence shows that anti-VEGF treatment has better refractive safety than laser
26
27
28 22 therapy for children with ROP. Because intraocular injection of angiogenesis

1 factor inhibitors is increasingly applied, we need more high-quality RCTs to
2 explore the issue further.

3 **Footnotes**

4 **Contributors:** Qi-Hang Kong and Xue-Song Mi conceived the idea of the article,
5 Qi-Hang Kong and Xue-Song Mi did the literature search. Qi-Hang Kong, Xue-
6 Song Mi, and Wai-kit Ming undertook the data acquisition and analysis. Qi-
7 Hang Kong carried out the manuscript preparation. Xue-Song Mi and Wai-kit
8 Ming were responsible for the revision of the manuscript. All authors have read
9 and approved the final manuscript.

10 **Funding:** The research did not receive any specific funding from any institution.

11 **Conflicts of Interest :** The author declares that the publication of this paper
12 has no financial support or conflict of interest.

13 **Provenance and peer review:** Not commissioned; externally peer-reviewed.

14 **Data sharing statement:** All data analyzed in this study are included in the
15 article and its supplementary files.

16 **Patient consent for publication:** Not required.

17

18

19

20

21

22

References

- 1 Chen J, Smith LE. Retinopathy of prematurity. *Angiogenesis*. 2007;10(2):133-40.
- 2 Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of Retinopathy of Prematurity-Use of Anti-VEGF Therapy. *Asia-Pacific journal of ophthalmology (Philadelphia, Pa)*. 2018;7(1):56-62.
- 3 Bashinsky AL. Retinopathy of Prematurity. *North Carolina medical journal*. 2017;78(2):124-8.
- 4 Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. *Lancet (London, England)*. 2013;382(9902):1445-57.
- 5 Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. *The American journal of pathology*. 2000;156(4):1337-44.
- 6 Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. *The Cochrane database of systematic reviews*. 2018;1(1):Cd009734.
- 7 Walz JM, Bemme S, Pielen A, et al. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. *Acta ophthalmologica*. 2016;94(8):e744-e52.
- 8 Tawse KL, Jeng-Miller KW, Baumal CR. Current Practice Patterns for Treatment of Retinopathy of Prematurity. *Ophthalmic surgery, lasers & imaging retina*. 2016;47(5):491-5.
- 9 VanderVeen DK, Melia M, Yang MB, et al. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. *Ophthalmology*. 2017;124(5):619-33.
- 10 Kang HG, Choi EY, Byeon SH, et al. Anti-vascular Endothelial Growth Factor Treatment of

1
2
3
4 Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. *Korean journal of*
5
6 *ophthalmology: KJO*. 2018;32(6):451-8.
7

8
9 **11** Kabataş EU, Kurtul BE, Altıaylık Özer P, et al. Comparison of Intravitreal Bevacizumab,
10
11 Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of
12
13 Prematurity in Turkish Preterm Children. *Current eye research*. 2017;42(7):1054-8.
14

15
16
17 **12** Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
18
19 meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)*. 2009;339:b2535.
20

21
22 **13** Wells GA SD, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
23
24 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *ohrica*
25
26 http://www.ohrica.com/programs/clinical_epidemiology/oxford.asp; 2000; Accessed 25 Jul 2020.
27
28

29
30 **14** Gu WJ, Hou BL, Kwong JSW, et al. Association between intraoperative hypotension and
31
32 30-day mortality, major adverse cardiac events, and acute kidney injury after non-cardiac
33
34 surgery: A meta-analysis of cohort studies. *International journal of cardiology*. 2018;258:68-73.
35
36

37
38 **15** Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*
39
40 *(Clinical research ed)*. 2003;327(7414):557-60.
41

42
43 **16** Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab
44
45 monotherapy compared with conventional laser treatment: a randomized clinical trial. *JAMA*
46
47 *ophthalmology*. 2014;132(11):1327-33.
48
49

50
51 **17** O'Keefe N, Murphy J, O'Keefe M, et al. Bevacizumab compared with diode laser in stage 3
52
53 posterior retinopathy of prematurity: A 5 year follow up. *Irish medical journal*. 2016;109(2):355.
54

55
56 **18** Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy
57
58 of prematurity: refractive error results. *American journal of ophthalmology*. 2013;155(6):1119-
59
60

1
2
3
4 24.e1.
5

6
7 **19** Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after Intravitreal Bevacizumab
8
9 versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
10
11 *Ophthalmology*. 2015;122(5):1008-15.
12

13
14 **20** Kuo HK, Sun IT, Chung MY, et al. Refractive Error in Patients with Retinopathy of
15
16 Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. *Ophthalmologica*
17
18 *Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur*
19
20 *Augenheilkunde*. 2015;234(4):211-7.
21
22

23
24 **21** Kang HG, Kim TY, Han J, et al. Refractive Outcomes of 4-Year-old Children after Intravitreal
25
26 Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of
27
28 Prematurity. *Korean journal of ophthalmology: KJO*. 2019;33(3):272-8.
29
30

31
32 **22** Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with
33
34 bevacizumab versus laser. *Journal of AAPOS: the official publication of the American*
35
36 *Association for Pediatric Ophthalmology and Strabismus*. 2015;19(2):140-4.
37
38

39
40 **23** Vujanovic MS, Stankovic-Babic GL, Oros A, et al. Refractive errors in premature infants with
41
42 retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy.
43
44 *Vojnosanitetski Pregled*. 2017;74(4):323-8.
45
46

47
48 **24** Gunay M, Sukgen EA, Celik G, et al. Comparison of Bevacizumab, Ranibizumab, and Laser
49
50 Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. *Current eye*
51
52 *research*. 2017;42(3):462-9.
53
54

55
56 **25** Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their
57
58 correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular
59
60

1
2
3
4 endothelial growth factors or laser photocoagulation. *The British journal of ophthalmology*.

5
6
7 2020;104(5):691-6.

8
9 **26** Lee YS, See LC, Chang SH, et al. Macular Structures, Optical Components, and Visual
10
11 Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. *American*
12
13 *journal of ophthalmology*. 2018;192:20-30.

14
15
16
17 **27** Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of Intravitreal Bevacizumab
18
19 and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. *Ophthalmology*
20
21 *Retina*. 2018;2(9):942-8.

22
23
24
25 **28** Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for
26
27 retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A
28
29 meta-analysis and systematic review. *PloS one*. 2019;14(12):e0225643.

30
31
32
33 **29** Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity. *American journal of*
34
35 *ophthalmology*. 2008;145(6):1090-4.

36
37
38 **30** Al-Otaibi AG, Aldrees SS, Mousa AA. Long term visual outcomes in laser treated threshold
39
40 retinopathy of prematurity in Central Saudi Arabia. *Saudi journal of ophthalmology : official*
41
42 *journal of the Saudi Ophthalmological Society*. 2012;26(3):299-303.

43
44
45
46 **31** Cook A, White S, Batterbury M, et al. Ocular growth and refractive error development in
47
48 premature infants with or without retinopathy of prematurity. *Investigative ophthalmology &*
49
50 *visual science*. 2008;49(12):5199-207.

51
52
53
54 **32** Chen TC, Tsai TH, Shih YF, et al. Long-term evaluation of refractive status and optical
55
56 components in eyes of children born prematurely. *Investigative ophthalmology & visual science*.
57
58 2010;51(12):6140-8.

1
2
3
4 **33** Wu WC, Lin RI, Shih CP, et al. Visual acuity, optical components, and macular abnormalities
5
6 in patients with a history of retinopathy of prematurity. *Ophthalmology*. 2012;119(9):1907-16.
7

8
9 **34** Gunay M, Sekeroglu MA, Bardak H, et al. Evaluation of Refractive Errors and Ocular
10
11 Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. *Strabismus*.
12
13
14 2016;24(2):84-8.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure legends

Figure 1 Selection of studies for the meta-analysis

Figure 2 Forest plot of spherical equivalent.

Figure 3 Forest plot of the effect anti-VEGF therapy on spherical equivalent, according to the types of article included

Figure 4 Forest plot of axial length (AL)

Figure 5 Forest plot of anterior chamber depth (ACD).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1

215x184mm (120 x 120 DPI)




Figure2

340x158mm (96 x 96 DPI)




Figure3

296x194mm (96 x 96 DPI)




Figure4

347x85mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure5
298x67mm (96 x 96 DPI)

S1 strategy.

Detailed search strategy for PubMed

1. Retinopathy of Prematurity[MeSH]

2. Prematurity Retinopath*[Tiab] OR Retrolental Fibroplasia*[Tiab] OR

Fibroplasia* Retrolental[Tiab]

3.1 OR 2

4. Anti-VEGF[MeSH]

5. Mvasi[Tiab] OR Avastin[Tiab] OR Ranibizumab[Tiab] OR aflibercept[Tiab]

OR Anti-vascular endothelial growth factor[Tiab]

6.4 OR 5

7. Error*,Refractive[MeSH]


8. Error*,Refractive[Tiab] OR Refractive Error*[Tiab] OR

Disorder*,Refractive[Tiab] OR Ametropia[Tiab]


9.7 OR 8

10 3 AND 6 AND 9

S2 forest plot :Forest plot of lens thickness (LT).



S3 funnel plot: Publication bias was evaluated by the funnel plot.





PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4,5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7,8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6,7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6(S1 strategy)
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7,8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7,8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8,9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10(Table1)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13(S2 funnel plot)
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18,19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Refractive Outcomes After Intravitreal Injection of Anti-vascular Endothelial Growth Factor Versus Laser Photocoagulation for Retinopathy of Prematurity: a Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042384.R1
Article Type:	Original research
Date Submitted by the Author:	29-Oct-2020
Complete List of Authors:	Kong, Qihang; Jinan University, Ophthalmology Ming, Wai-kit; Jinan University, Department of Public Health and Preventive Medicine; Hong Kong University, Li Ka Shing Faculty of Medicine Mi, xue-song; Jinan University, Ophthalmology
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Surgery, Ophthalmology, Paediatrics
Keywords:	Paediatric ophthalmology < OPHTHALMOLOGY, Medical ophthalmology < OPHTHALMOLOGY, Paediatric surgery < SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Refractive Outcomes After Intravitreal Injection of Anti-vascular**
5
6 **Endothelial Growth Factor Versus Laser Photocoagulation for**
7
8 **Retinopathy of Prematurity: a Meta-analysis**
9
10

11 Qi-Hang Kong, MBBS¹ Wai-kit Ming, MD, PhD, MPH^{2,3}, Xue-Song Mi, MD, PhD¹

12
13
14 1.Department of Ophthalmology, the First Affiliated Hospital of Jinan University, Guangzhou,
15 Guangdong Province, China.

16
17
18 2.Department of Public Health and Preventive Medicine, School of Medicine, Jinan University,
19 Guangzhou, China

20
21
22 3.Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

23
24 **Corresponding Author:**

25
26
27 Xue-Song Mi, MD, PhD, Department of Ophthalmology, the First Affiliated
28 Hospital of Jinan University, Guangzhou, Guangdong Province, China.

29
30
31 **Phone number:**+86 17665185740

32
33
34 **E-mail address:**kqh211@stu2018.jnu.edu.cn

35
36
37 Wai-kit Ming, MD, PhD, MPH, 1.Department of Public Health and Preventive
38 Medicine, School of Medicine, Jinan University, Guangzhou, China, 2.Li Ka
39 Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

40
41
42
43
44
45 **Phone number:**+86 15625012076

46
47
48 **E-mail address:** 2981365101@qq.com

49
50
51 **Total number of tables plus figures:**6

52
53 **Funding:** The study is supported by the National NSFC (82074169), Hygiene
54 & Health Appropriated Technology and Promoting Project of Guangdong
55 Province (202006130025341204, 201905270933056876)
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conflicts of interest: The author declares that the publication of this paper has no financial support or conflict of interest.

Key words: Retinopathy of Prematurity; Anti-VEGF; Refractive Errors; myopia

For peer review only

1 **Abstract**

2 **Objective:** To determine the effects of the intraocular injection of anti-vascular
3 endothelial growth factor (anti-VEGF) drugs on the refractive status of infants
4 with retinopathy of prematurity(ROP).

5 **Design:** Systematic review and meta-analysis of the refractive status of infants
6 with ROP who receive anti-VEGF drugs .

7 **Data sources:**The PubMed,Web of Science,and EMBASE databases and the
8 ClinicalTrials.gov website were searched up to June 2020.

9 **Eligibility criteria when selecting studies:** We included randomized
10 controlled trials (RCTs) and observational studies that compared refractive
11 errors between anti-VEGF drug and laser therapies.

12 **Data extraction and synthesis:** Data extraction and risk-of-bias assessments
13 were conducted by two independent reviewers. We used a random-effects
14 model to pool outcomes. The outcome measures were the spherical
15 equivalent, axial length (AL), anterior chamber depth (ACD), and lens
16 thickness (LT).

17 **Results:** Thirteen studies involving 1850 eyes were assessed: 914 in the anti-
18 VEGF drug group, and 936 in the control (laser) group. Children who received
19 anti-VEGF drug treatment had less myopia than those who received laser
20 therapy (mean difference =1.80 diopter, 95% confidence interval =: 0.97 to 2.63,
21 $P < 0.0001$, $I^2 = 78\%$). The AL, ACD, and LT did not reach statistical
22 significance difference between the two groups.The current evidence indicates

1
2
3
4 1 that the refractive safety in children with ROP is better for anti-VEGF drug
5
6 2 treatment than for laser therapy.

7
8
9 3 **Conclusions:**This meta-analysis indicates that anti-VEGF drug therapy
10
11 4 results in less myopia compared with laser therapy. However, there are
12
13 5 relatively few published articles on refractive errors in ROP , and so high-
14
15 6 quality and powerful RCTs are needed in the future.

16
17
18
19 7 **PROSPERO registration number:** CRD42020160673

20 8 **Strengths and limitations of this study**

21
22
23
24
25 9 Our meta-analysis adhered to the methodology recommendations of the
26
27 10 Cochrane Handbook. We conducted a thorough literature search.

28
29
30 11 The article describes a review protocol that is formally registered on
31
32 12 PROSPERO, and the study was conducted and reported on using rigorous
33
34 13 methods following the PRISMA statement.

35
36
37 14 We included other parameters that may affect the refractive errors in children
38
39 15 with ROP in our meta-analysis, such as ACD, LT,and AL

40
41
42 16 The refractive error measures were from different follow-up time points across
43
44 17 studies, this may confound the evaluation of refractive error differences
45
46 18 between anti-VEGF and laser

47
48
49 19 Most of the included studies had an observational design,with only two RCTs
50
51 20 being included, The inclusion of more RCTs would have allowed more-reliable
52
53 21 conclusions to be drawn.

54 22 **Introduction**

1 Retinopathy of prematurity (ROP) is a common cause of blindness in developed
2 countries and its prevalence is increasing in developing countries.¹
3 Characterized by retinal ischemia, aberrant angiogenesis, fibrovascular
4 proliferation, and progressive vitreoretinal traction, ROP accounts for 14% and
5 20% of cases of childhood blindness in the United States and developing
6 countries, respectively.²
7 ROP is a unique retinal vascular proliferative disease occurring in premature
8 and low-birth-weight infants.³ Retinal vascularization normally occurs at around
9 12 weeks of gestation and is completed by 36-40 weeks. This prolonged
10 development period means that the retinal system is immature when infants
11 leave the uterus prematurely. The loss of the maternal interaction environment
12 and exposure to high oxygen levels in premature infants can lead to the
13 cessation of retinal vascularization, damage to the capillary endothelium,
14 hypoxia of the retinal blood vessels, and stimulation of fibrovascular tissue
15 proliferation, and might even finally lead to traction retinal detachment.⁴
16 Laser photocoagulation has previously been the mainstay treatment for ROP.
17 While this intervention is effective and safe, a few defects can remain, such as
18 high myopia, visual field loss, and retinal destruction. An intensive study of ROP
19 found that the levels of vascular endothelial growth factor (VEGF) were
20 markedly elevated in the vitreous of eyes at stage-4 ROP.⁵ In a normally
21 developing retina, VEGF promotes the development of blood vessels from the
22 optic nerve to the periphery, whereas the overexpression of VEGF in preterm

1 infants leads to abnormal vascular proliferation.⁶ This situation has prompted,
2 researchers to use anti-VEGF drugs to treat ROP. Many studies have shown
3 that the intravitreal injection of anti-VEGF drugs may be an effective clinical
4 intervention for ROP.^{7,8,9} However, the effects of this intervention are relatively
5 short term, while its long-term complications remain unclear, such as
6 postoperative refractive errors. Kang et al.¹⁰ showed that anti-VEGF drugs do
7 not cause refractive errors after ROP treatment, while Kabatas et al.¹¹ found
8 that effects of the intravitreal injection of anti-VEGF drugs did not differ
9 significantly from those of laser photocoagulation, with both potentially
10 causing refractive errors.

11 The increasing clinical application of anti-VEGF drugs makes it important to
12 know whether these drugs can also cause refractive errors in children with ROP.
13 Hence, the purpose of the present meta-analysis was to determine the effects
14 of anti-VEGF drugs on the refractive status of ROP compared with laser
15 treatment, and to verify their clinical safety. The outcome measures considered
16 in this study were the spherical equivalents (SE), axial length (AL), anterior
17 chamber depth (ACD), and lens thickness (LT).

18 **Methods**

19 Our study is reported on here in accordance with the PRISMA guidelines for
20 meta-analyses.¹² The study has been registered on PROSPERO (registration
21 number CRD42020160673).

1 **Data sources and search strategy.**

2 From their inceptions to January 2020, we searched the PubMed, Web of
3 Science, EMBASE databases, and the ClinicalTrials.gov website using
4 keywords and medical subject headings. Only studies reported on in English
5 were considered for inclusion. We also searched the reference lists of the
6 selected articles to identify any other relevant articles. The search
7 terms included “retinopathy of prematurity,” “prematurity retinopathy,”
8 “retrolental fibroplasia,” “fibroplasia, retrolental,” “ROP,” “anti-VEGF,”
9 “bevacizumab,” “Avastin,” “Lucentis,” “ranibizumab,” “aflibercept,” “anti-
10 vascular endothelial growth factor,” “Mvasi,” and “refractive errors,” “disorders,
11 refractive,” and “ametropias.” The search strategy is detailed in the S1
12 strategy(online supplementary material).

13 **Study selection and eligibility criteria.**

14 Each study was independently screened by two of the authors (Q.H.K.and
15 M.X.S),with discrepancies between them resolved through discussion with the
16 third author (W.M.). The following inclusion criteria were applied : (1) children
17 who had been clearly diagnosed with ROP, (2) subjects in the intervention
18 group had received an intraocular injection of an anti-VEGF drug that can be
19 used in children with ROP,(3) subjects in the control group had received
20 treatment of the eye using a retinal argon or diode laser., (4)the outcome of
21 interest was the refractive status of the treated children with ROP , including

1 SE and ocular biometric structural features such as AL, ACD, and LT, and (5)
2 the study design was a randomized controlled trial (RCT) or an observational
3 study. We excluded children with stage-4 ROP, stage-5 ROP, or other eye
4 diseases such as congenital cataract or glaucoma prior to treatment.

5 **Data extraction and quality assessment.**

6 The following information was extracted for the included studies: name of the
7 first author, publication year, sample size, number of eyes, GA (gestational age),
8 BW (birth weight), follow-up time, type of anti-VEGF drug, dose of anti-VEGF
9 drug, and results data (SE, AL, ACD, and LT). When two anti-VEGF drugs had
10 been applied in a study, we extracted the data separately and compared the
11 data with the control group.

12 We entered the extracted data into an Excel file. Two of the authors (Q.H.K and
13 M.X.S.) assessed the quality of studies using the Newcastle-Ottawa
14 Scales (NOS).¹³ The NOS consists of four items for subject selection (maximum
15 4 points), one item for comparability between groups (maximum 2 points), and
16 three items for outcome measurement (maximum 3 points). The maximum
17 score is therefore 9 points, with studies considered to be of moderate quality
18 having scores of 4–6, and those of high quality having scores of 7–9.¹⁴

19 **Statistical analysis.**

20 The weighted mean differences (WMDs) with 95% confidence intervals (Cis)

1 were calculated for continuous variables. Heterogeneity between the included
2 studies was assessed using the I^2 statistic. I^2 values of 25%-50%, 50%-
3 75%,75%-100% were considered to indicate low, moderate, and high
4 heterogeneity,respectively.¹⁵ Due to the possibility of heterogeneity being
5 present between studies, we used a more-conservative version of the random-
6 effects model.

7 A visual funnel plot was used to evaluate publication bias,with an asymmetric
8 plot indicating that publication bias was present. Egger's test was further used
9 to provide accurate assessments of publication bias, with if $P < 0.05$, considered
10 to indicate some degree of publication bias.

11 All statistical analyses were performed using RevMan software (version 5.3,
12 Nordic Cochrane Centre) and Stata software (version 12.0, Stata Corporation).

13 **Results**

14 **Literature search.**

15 The initial literature search identified 121 records. After screening the titles and
16 Abstracts, 31 potentially eligible studies were assessed for inclusion. After
17 reading the full texts ,13 studies were finally included in the present meta-
18 analysis. The study selection process is illustrated in **Figure 1**.

19 The 13 selected studies comprised 2 RCTs^{16, 17} and 11 observational studies^{11,}
20 ¹⁸⁻²⁷. According to the scoring criteria of the NOS, 11 studies were evaluated as
21 being of high quality, while 2 were evaluated as being of moderate quality. The
22 NOS score of the included studies ranged from 6 to 8,with a median of 8. All of

1 the articles had been published between 2013 and 2019. The sample sizes in
2 the studies ranged from 12 to 397, with a total of 1850 eyes: 914 in the anti-
3 VEGF drug group and 936 in the control group. The included anti-VEGF drugs
4 were bevacizumab and ranibizumab.,with 1.of these drugs administered in 12
5 studies and 2 drugs administered in 1 study.The dose of anti-VEGF drugs also
6 varied among the included studies,from a minimum of 0.2mg to a maximum of
7 was 1.25mg, with most of the studies using 0.625 mg.

8 After injecting anti-VEGF drugs, children with ROP were followed regularly for
9 more than 6 months, ranging from 9 months to 5 years. SE values were
10 reported for all of the 13 included studies, while ALs, ACDs, and LTs were
11 reported for 4, 3, and 2 studies, respectively. We presented the main
12 information within the included studies in our meta-analysis (**Table 1**)

Table 1: Main Characteristics of Studies Included in the Meta-analysis

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Harder 2013 ¹⁸	Germany	Anti-VEGF	12/23	25.20 ± 1.60	622.00 ± 153.00	12	bevacizumab	0.375 or 0.625	7
		laser	13/26	25.30± 1.80	717.00 ± 197.00				
Hwang 2015 ¹⁹	American	Anti-VEGF	11/22	NA	668.10 ± 127.30	21.7	bevacizumab	0.625	8
		laser	17/32		701.40 ± 118.80	32.5			
Kabataş 2017 ¹¹ *	Turkey	Anti-VEGF	12/24	26.10 ± 2.27	841.00 ± 235.00	18	bevacizumab	0.625	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kabataş 2017 ¹¹ *	Turkey	Anti-VEGF	6/12	26.00 ± 1.26	840.00 ± 177.00	18	ranibizumab	0.25	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kuo 2015 ²⁰	Taiwan	Anti-VEGF	15/15	27.33 ± 2.94	1,079.67 ± 357.48	3 years	bevacizumab	0.5	7
		laser	14/14	27.43± 2.93	1,006.79 ± 327.65	of age			
Kang 2019 ²¹	Korea	Anti-VEGF	12/22	27.40 ± 2.00	983.20 ± 265.60	4 years	bevacizumab	0.625	7
		laser	15/30	34.00 ± 2.90	961.00 ± 286.50	of age	ranibizumab	0.2	
Isaac 2015 ²²	Canada	Anti-VEGF	13/23	25.20 ± 1.40	722.00 ± 131.00	16.00±6.00	bevacizumab	0.625	8
		laser	12/22	25.00 ± 1.10	674.00 ± 175.00	6.00±3.00			
Vujanović2017 ²³	Serbia	Anti-VEGF	21/42	29.00 ± 4.00	1,175.00 ± 425.00	9	bevacizumab	0.625	8
		laser	45/90	30.00 ± 4.00	1,200.00 ± 500.00				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1 (continued)

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Gunay 2016 ²⁴	Turkey	Anti-VEGF	55/107	27.31 ± 2.18	1005.29 ± 411.19	19.40±6.43	bevacizumab	0.625	8
*		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Gunay 2016 ²⁴	Turkey	Anti-VEGF	22/44	27.95 ± 2.90	1195.90 ± 466.98	18.96±4.79	ranibizumab	0.25	8
*		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Chen 2019 ²⁵	Taiwan	Anti-VEGF	13/25	26.46 ± 1.51	862.54 ± 197.65	NA	bevacizumab	0.625	7
		laser	12/22	25.50 ± 1.24	815.83 ± 151.07				
Lee 2018 ²⁶	Taiwan	Anti-VEGF	17/33	26.60 ± 1.60	874.10 ± 228.70	> 48	bevacizumab	0.625	6
		laser	13/24	26.60 ± 2.50	803.10 ± 144.90				
Roohipoor 2018 ²⁷	Iran	Anti-VEGF	NA/397	27.8	1146	> 12	bevacizumab	0.625	8
		laser	NA/190						
Geloneck 2014 ^{16*}	American	Anti-VEGF	56/110	24.3	625	2.5 years of age	bevacizumab	0.625	8
		laser	53/101						
O'Keeffe 2016 ^{17*}	Irish	Anti-VEGF	15/15	25±1.25	780±135	60	bevacizumab	1.25	6
		laser	15/15						

*: RCT, Randomized Controlled Trial; NOS: Newcastle-Ottawa Scale; NA: not applicable; GA: gestational age; BW: birth weight;

* : There are two types of Anti-VEGF drugs included in the literature, so the details are listed separately

1 **Main outcomes**

2 **Spherical equivalent.** The SE values were reported for 914 eyes in the anti-
3 VEGF drug group and 936 eyes in the control group. (**Figure 2**). The SE values
4 were higher in the anti-VEGF drug group than in the control group (MD=1.80
5 diopter, 95% CI=0.97 to 2.63),with a high heterogeneity ($I^2 = 78\%$). The findings
6 of the subgroup analysis of the SE according to type of article are summarized
7 in **Figure 3**. At the same time, according to different types of anti-VEGF
8 drugs(Online supplementary material S2 forest plot) and different follow-up time
9 (Online supplementary material S3 forest plot), we conducted a subgroup
10 analysis.

11 **Axial length.** Three articles^{23, 25, 26} reported the AL, with 251 eyes in the anti-
12 VEGF drug group and 362 eyes in the control group. (**Figure 4**). There was no
13 significant difference in the AL between the groups (MD=-0.04mm, 95%CI: -
14 0.30 to 0.21), and the heterogeneity was low ($I^2 = 30\%$).

15 **Anterior chamber depth.** Three articles^{23, 25, 26} reported the ACD in children
16 with ROP who were or were not taking anti-VEGF drugs. We found no
17 difference in the ACD between the anti-VEGF drug and control
18 groups(MD=0.19mm; 95% CI=-0.14 to 0.52, $I^2 = 85\%$).(Figure 5) There was
19 high heterogeneity($I^2 = 85\%$), but excluding Vujanović's study in the sensitivity
20 analysis resulted in moderate heterogeneity (MD= 0.39mm; 95% CI=-0.06 to
21 0.84, $I^2 = 64\%$).

22 **Lens thickness.** Two articles^{23, 25} reported the LT,which did not differ

1 significantly between the anti-VEGF drug and laser groups (MD=0.06mm; 95%
2 CI: -0.56 to 0.67, P =0.85), and I^2 was 97%. (online supplementary material:
3 S4 forest plot).

4 **Publication bias**

5 Visual examinations of funnel plots constructed using Stata software. and also
6 statistical calculations using in Egger's test did not reveal any publication bias
7 (P =0.401). (online supplementary material S5 funnel plot)

8 **Discussion**

9 The present meta-analysis identified that 13 previous studies have investigated
10 the association between treatments and refractive errors among children with
11 ROP, and analyzed SE, AL, ACD, and LT. A significant difference in SE was
12 found between the two study groups.,This means that anti-VEGF drug
13 treatment reduces myopia in children with ROP compared with laser treatment,
14 as consistently found in both the comprehensive and subgroup analyses.
15 However, no significant difference were found in the other variables analyzed
16 in this study.

17 Meta-analyses of similar subjects have also been reported.²⁸ The meta-
18 analysis of Tan et al. included 7 articles covering 519 eyes, but this was limited
19 to the anti-VEGF drug bevacizumab. Although the main finding of our meta-
20 analysis was consistent with previous meta-analyses, there are some
21 differences between them. Firstly, our study analyzed the largest amount of
22 data(13 articles covering 1850 eyes) and included some recently published

1 literature, which increased the statistical power of the analyses. Secondly, in
2 addition to the anti-VEGF drug bevacizumab, another anti-VEGF drug that is
3 commonly used in clinical practice was also included (ranibizumab), which
4 makes the present conclusions closer to clinical reality. Thirdly, we added other
5 ocular parameters to investigate how anti-VEGF drug and laser therapies affect
6 refractive errors: ACD, LT, and AL. A previous study showed that these ocular
7 refractive parameters may be related to myopic adults with ROP,²⁹ but no
8 evidence was provided for laser treatment and anti-VEGF drug treatment
9 exerting different effects on the refractive status in children with ROP. We
10 therefore analyzed these ocular parameters in laser and anti-VEGF drug
11 groups, with the obtained results providing further evidence that anti-VEGF
12 drug treatment is safe for children with ROP.

13 This meta-analysis of 13 articles synthesized the literature to evaluate the
14 refractive safety of anti-VEGF drugs for children with ROP, and has shown that
15 anti-VEGF drug treatment provides better refractive results than does laser
16 treatment. As seen in previous studies, myopia was reduced more by anti-
17 VEGF drug therapy than by laser treatment in the current study. Most previous
18 studies have quantified refractive errors using SE values, since this parameter
19 is considered the primary measure of such errors, and so we also used this
20 parameter to explore group differences .

21 Kuo et al²⁰ and Issec et al.²² reported that refractive errors did not differ
22 significantly between anti-VEGF drug and laser groups. However, our meta-

1
2
3
4 1 analysis found that anti-VEGF drug therapy reduces myopia and refractive
5
6 2 errors more than does laser treatment. Two factors may explain this
7
8
9 3 difference.(1)both of the previous studies included small samples ,and(2) a
10
11 4 higher proportion of the children included in the present study had severe ROP.
12
13
14 5 The present findings indicate that anti-VEGF drug therapy may be an
15
16 6 alternative to laser therapy for reducing refractive errors in children with ROP.
17
18
19 7 Our subgroup analysis found that anti-VEGF drug therapy exerted better effects
20
21 8 on refractive errors than did laser therapy, based on findings in both RCTs and
22
23 9 observational studies.
24
25
26
27 10 Laser therapy has been considered the first choice of treatment for ROP and
28
29 11 has well-established safety and efficacy.However, this approach results in the
30
31 12 retina being permanently cauterized, leading to inadequate vascularization and
32
33 13 the risk of visual field loss, high myopia, and cataracts. Regarding refraction, it
34
35 14 has also been reported that laser treatment may be a risk factor for refractive
36
37 15 errors in children with ROP.³⁰ Therefore, the impact of future damage to the
38
39 16 refractive status that may result from laser treatment needs to be considered
40
41 17 when treating children with ROP, indicating the need to find a treatment method
42
43 18 with increased effectiveness and safety. A previous in-depth study of the ROP
44
45 19 mechanism found that the intraocular injection of an anti-VEGF drug may be a
46
47 20 good alternative to laser treatment.²² The intraocular injection of anti-VEGF
48
49 21 drugs has the advantages of less trauma and pain, and involving an easy
50
51 22 procedure,which has resulted in it being increasingly used by a large number
52
53
54
55
56
57
58
59
60

1 of clinicians. This situation makes it essential to clarify the safety regarding
2 refractive errors as soon as possible, and the present meta-analysis has
3 provided good evidence for the refractive safety of anti-VEGF drugs.

4 Changes in the biometric structure of the eye—such as in ACD, LT, AL, corneal
5 curvature, and corneal diameter—may be related to increased refractive
6 errors.³¹⁻³³ We therefore regard it as essential to consider the above indicators
7 of ocular biometric structure when verifying the refractive status of children with
8 ROP. Although there have been previous meta-analyses of refractive outcomes
9 after treatment of ROP with anti-VEGF drug therapy, none of these meta-
10 analyses explored the relationship between refractive outcomes and the
11 biometric structure of the eye when comparing anti-VEGF drug and laser
12 therapies. Our study found no significant intergroup differences in these
13 parameters. There is also considerable debate about whether anti-VEGF drug
14 treatment of ROP will induce changes in ocular parameters. Lee et al found that
15 AL did not differ among different treatment groups. Gunay et al³⁴ reported that
16 in children who receive anti-VEGF drug therapy, the AL might be related to the
17 development of myopia and is not related to the ACD or LT. The BEAT-ROP
18 believes that anti-VEGF drug treatment may facilitate the continuation of the
19 local growth factor expression and signaling pathways, allowing the anterior
20 segment to develop normally¹⁶. The small number of articles that have reported
21 on the ocular biometric structure makes it difficult to draw definitive conclusions,
22 and so more high-quality RCTs are needed to verify the impact of anti-VEGF

1
2
3
4 1 drugs on the ocular biometric structure.
5
6 2 We consider that future research should focus on two main aspects. Firstly,
7
8
9 3 there is no unified standard for the optimal dose of anti-VEGF drugs to use in
10
11 4 the treatment of ROP. Most clinical applications used doses are half of the
12
13
14 5 adults, but if other doses of anti-VEGF treatment of ROP affect the result, we
15
16
17 6 do not know, so in the future, a clear plan for the dose of anti-VEGF needs to
18
19
20 7 be proposed. Secondly, there is no clear standard for the follow-up time of
21
22 8 children with ROP. The conclusions that may be drawn lack credibility if the
23
24
25 9 follow-up time is too short, and so the most-appropriate follow-up time of
26
27
28 10 children after treatment with anti-VEGF drugs also needs to be determined.
29
30 11 The first strength of our meta-analysis is that it adhered to the methodology
31
32 12 recommendations of the Cochrane Handbook, and included conducting a
33
34
35 13 thorough literature search. Secondly, this meta-analysis has a formal registered
36
37
38 14 review protocol on PROSPERO, and our investigations were conducted and
39
40
41 15 reported with rigorous methods following the PRISMA statement. Thirdly, our
42
43
44 16 meta-analysis included other parameters that may affect the refractive errors in
45
46
47 17 children with ROP, such as ACD, LT, and AL. The results further strengthen
48
49
50 18 the evidence for the safety of anti-VEGF drugs in children with ROP. However,
51
52
53 19 our study also had certain limitations. First, the refractive error measures were
54
55
56 20 from different follow-up time points across studies, this may confound the
57
58
59 21 evaluation of refractive error differences between anti-VEGF and
60 22 laser. Second, most of the included studies had an observational design, with

1 only two RCTs being included, The inclusion of more RCTs would have allowed
2 more-reliable conclusions to be drawn.

3 **Conclusions**

4 In conclusion, the present meta-analysis has shown that anti-VEGF drug
5 therapy reduces myopia more effectively than does laser treatment. The current
6 evidence indicates that anti-VEGF drug treatment has better refractive safety
7 than laser therapy for children with ROP. Since intraocular injections of
8 angiogenesis factor inhibitors are increasingly being applied, more high-quality
9 RCTs are required.

10 **Footnotes**

11 **Contributors:** Qi-Hang Kong and Xue-Song Mi conceived the idea of the article,
12 Qi-Hang Kong and Xue-Song Mi did the literature search. Qi-Hang Kong, Xue-
13 Song Mi, and Wai-kit Ming undertook the data acquisition and analysis. Qi-
14 Hang Kong carried out the manuscript preparation. Xue-Song Mi and Wai-kit
15 Ming were responsible for the revision of the manuscript. All authors have read
16 and approved the final manuscript.

17 **Funding:** The study is supported by the National NSFC (82074169), Hygiene
18 & Health Appropriated Technology and Promoting Project of Guangdong
19 Province (202006130025341204, 201905270933056876)

20 **Conflicts of Interest :** The author declares that the publication of this paper
21 has no financial support or conflict of interest.

22 **Provenance and peer review:** Not commissioned; externally peer-reviewed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 **Data sharing statement:** All data analyzed in this study are included in the
- 2 article and its supplementary files.

Patient and Public Involvement: No patient involved

For peer review only

References

- 1
2
3
4 1 Chen J, Smith LE. Retinopathy of prematurity. *Angiogenesis*. 2007;10(2):133-40.
- 5
6
7 2 Tran KD, Cernichiario-Espinosa LA, Berrocal AM. Management of Retinopathy of Prematurity-
8
9 -Use of Anti-VEGF Therapy. *Asia-Pacific journal of ophthalmology (Philadelphia, Pa)*.
10
11 2018;7(1):56-62.
- 12
13
14 3 Bashinsky AL. Retinopathy of Prematurity. *North Carolina medical journal*. 2017;78(2):124-8.
- 15
16
17 4 Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. *Lancet (London, England)*.
18
19 2013;382(9902):1445-57.
- 20
21
22 5 Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte
23
24 growth factor levels are differentially elevated in patients with advanced retinopathy of
25
26 prematurity. *The American journal of pathology*. 2000;156(4):1337-44.
- 27
28
29 6 Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for
30
31 treatment of retinopathy of prematurity. *The Cochrane database of systematic reviews*.
32
33 2018;1(1):Cd009734.
- 34
35
36 7 Walz JM, Bemme S, Pielen A, et al. The German ROP Registry: data from 90 infants treated
37
38 for retinopathy of prematurity. *Acta ophthalmologica*. 2016;94(8):e744-e52.
- 39
40
41 8 Tawse KL, Jeng-Miller KW, Baumal CR. Current Practice Patterns for Treatment of
42
43 Retinopathy of Prematurity. *Ophthalmic surgery, lasers & imaging retina*. 2016;47(5):491-5.
- 44
45
46 9 VanderVeen DK, Melia M, Yang MB, et al. Anti-Vascular Endothelial Growth Factor Therapy
47
48 for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American
49
50 Academy of Ophthalmology. *Ophthalmology*. 2017;124(5):619-33.
- 51
52
53 10 Kang HG, Choi EY, Byeon SH, et al. Anti-vascular Endothelial Growth Factor Treatment of
54
55 Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. *Korean journal of*
56
57
58
59
60

1
2
3
4 *ophthalmology: KJO*. 2018;32(6):451-8.
5

6
7 **11** Kabataş EU, Kurtul BE, Altıaylık Özer P, et al. Comparison of Intravitreal Bevacizumab,
8
9 Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of
10
11 Prematurity in Turkish Preterm Children. *Current eye research*. 2017;42(7):1054-8.
12

13
14 **12** Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
15
16 meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)*. 2009;339:b2535.
17

18
19 **13** Wells GA SD, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
20
21 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *ohrica*
22
23 http://www.ohrica/programs/clinical_epidemiology/oxfordasp; 2000; Accessed 25 Jul 2020.
24
25

26
27 **14** Gu WJ, Hou BL, Kwong JSW, et al. Association between intraoperative hypotension and
28
29 30-day mortality, major adverse cardiac events, and acute kidney injury after non-cardiac
30
31 surgery: A meta-analysis of cohort studies. *International journal of cardiology*. 2018;258:68-73.
32
33

34
35 **15** Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*
36
37 *(Clinical research ed)*. 2003;327(7414):557-60.
38

39
40 **16** Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab
41
42 monotherapy compared with conventional laser treatment: a randomized clinical trial. *JAMA*
43
44 *ophthalmology*. 2014;132(11):1327-33.
45
46

47
48 **17** O'Keefe N, Murphy J, O'Keefe M, et al. Bevacizumab compared with diode laser in stage 3
49
50 posterior retinopathy of prematurity: A 5 year follow up. *Irish medical journal*. 2016;109(2):355.
51
52

53
54 **18** Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy
55
56 of prematurity: refractive error results. *American journal of ophthalmology*. 2013;155(6):1119-
57
58 24.e1.
59
60

1
2
3
4 **19** Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after Intravitreal Bevacizumab
5
6 versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
7
8
9 *Ophthalmology*. 2015;122(5):1008-15.

10
11 **20** Kuo HK, Sun IT, Chung MY, et al. Refractive Error in Patients with Retinopathy of
12
13 Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. *Ophthalmologica*
14
15 *Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur*
16
17 *Augenheilkunde*. 2015;234(4):211-7.

18
19
20
21 **21** Kang HG, Kim TY, Han J, et al. Refractive Outcomes of 4-Year-old Children after Intravitreal
22
23 Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of
24
25 Prematurity. *Korean journal of ophthalmology: KJO*. 2019;33(3):272-8.

26
27
28
29 **22** Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with
30
31 bevacizumab versus laser. *Journal of AAPOS: the official publication of the American*
32
33 *Association for Pediatric Ophthalmology and Strabismus*. 2015;19(2):140-4.

34
35
36
37 **23** Vujanovic MS, Stankovic-Babic GL, Oros A, et al. Refractive errors in premature infants with
38
39 retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy.
40
41
42 *Vojnosanitetski Pregled*. 2017;74(4):323-8.

43
44
45
46 **24** Gunay M, Sukgen EA, Celik G, et al. Comparison of Bevacizumab, Ranibizumab, and Laser
47
48 Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. *Current eye*
49
50 *research*. 2017;42(3):462-9.

51
52
53 **25** Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their
54
55 correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular
56
57 endothelial growth factors or laser photocoagulation. *The British journal of ophthalmology*.
58
59
60

1
2
3
4 2020;104(5):691-6.
5

6 **26** Lee YS, See LC, Chang SH, et al. Macular Structures, Optical Components, and Visual
7
8 Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. *American*
9
10 *journal of ophthalmology*. 2018;192:20-30.
11
12

13
14 **27** Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of Intravitreal Bevacizumab
15
16 and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. *Ophthalmology*
17
18 *Retina*. 2018;2(9):942-8.
19
20

21
22 **28** Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for
23
24 retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A
25
26 meta-analysis and systematic review. *PloS one*. 2019;14(12):e0225643.
27
28

29
30 **29** Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity. *American journal of*
31
32 *ophthalmology*. 2008;145(6):1090-4.
33
34

35
36 **30** Al-Otaibi AG, Aldrees SS, Mousa AA. Long term visual outcomes in laser treated threshold
37
38 retinopathy of prematurity in Central Saudi Arabia. *Saudi journal of ophthalmology : official*
39
40 *journal of the Saudi Ophthalmological Society*. 2012;26(3):299-303.
41
42

43
44 **31** Cook A, White S, Batterbury M, et al. Ocular growth and refractive error development in
45
46 premature infants with or without retinopathy of prematurity. *Investigative ophthalmology &*
47
48 *visual science*. 2008;49(12):5199-207.
49

50
51 **32** Chen TC, Tsai TH, Shih YF, et al. Long-term evaluation of refractive status and optical
52
53 components in eyes of children born prematurely. *Investigative ophthalmology & visual science*.
54
55 2010;51(12):6140-8.
56
57

58
59 **33** Wu WC, Lin RI, Shih CP, et al. Visual acuity, optical components, and macular abnormalities
60

1
2
3
4 in patients with a history of retinopathy of prematurity. *Ophthalmology*. 2012;119(9):1907-16.
5

6 **34** Gunay M, Sekeroglu MA, Bardak H, et al. Evaluation of Refractive Errors and Ocular
7
8 Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. *Strabismus*.
9
10
11
12 2016;24(2):84-8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure legends

Figure 1 Selection of studies for the meta-analysis

Figure 2 Forest plot of spherical equivalent.

Figure 3 Forest plot of the effect anti-VEGF therapy on spherical equivalent, according to the types of article included

Figure 4 Forest plot of axial length (AL)

Figure 5 Forest plot of anterior chamber depth (ACD).




Figure 1




Figure 2




Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4




Figure 5

S1 strategy.

Detailed search strategy for PubMed

1. Retinopathy of Prematurity[MeSH]

2. Prematurity Retinopath*[Tiab] OR Retrolental Fibroplasia*[Tiab]OR

Fibroplasia* Retrolental[Tiab]

3.1 OR 2

4. Anti-VEGF[MeSH]

5. Mvasi[Tiab] OR Avastin[Tiab] OR Ranibizumab[Tiab] OR aflibercept[Tiab]

OR Anti-vascular endothelial growth factor[Tiab]

6.4 OR 5

7. Error*,Refractive[MeSH]


8. Error*,Refractive[Tiab] OR Refractive Error*[Tiab]OR

Disorder*,Refractive[Tiab] OR Ametropia[Tiab]


9.7 OR 8

10 3 AND 6 AND 9


S2 forest plot : Forest plot of the effect of different anti-VEGF drugs on spherical equivalent.




S3 forest plot : Forest plot of the influence of different follow-up time on spherical equivalent.



S4 forest plot :Forest plot of lens thickness (LT).



S5 funnel plot: Publication bias was evaluated by the funnel plot.



review only



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4,5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7,8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6,7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6(S1 strategy)
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7,8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7,8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8,9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10(Table1)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13(S2 funnel plot)
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18,19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

BMJ Open

Refractive Outcomes After Intravitreal Injection of Anti-vascular Endothelial Growth Factor Versus Laser Photocoagulation for Retinopathy of Prematurity: a Meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042384.R2
Article Type:	Original research
Date Submitted by the Author:	17-Jan-2021
Complete List of Authors:	Kong, Qihang; Jinan University, Ophthalmology Ming, Wai-kit; Jinan University, Department of Public Health and Preventive Medicine; Hong Kong University, Li Ka Shing Faculty of Medicine Mi, xue-song; Jinan University, Ophthalmology
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Surgery, Ophthalmology, Paediatrics
Keywords:	Paediatric ophthalmology < OPHTHALMOLOGY, Medical ophthalmology < OPHTHALMOLOGY, Paediatric surgery < SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Refractive Outcomes After Intravitreal Injection of Anti-vascular**
5
6 **Endothelial Growth Factor Versus Laser Photocoagulation for**
7
8 **Retinopathy of Prematurity: a Meta-analysis**
9
10

11 Qi-Hang Kong, MBBS¹ Wai-kit Ming, MD, PhD, MPH^{2,3}, Xue-Song Mi, MD, PhD¹

12
13
14 1.Department of Ophthalmology, the First Affiliated Hospital of Jinan University, Guangzhou,
15 Guangdong Province, China.

16
17
18 2.Department of Public Health and Preventive Medicine, School of Medicine, Jinan University,
19 Guangzhou, China

20
21
22 3.Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

23
24 **Corresponding Author:**

25
26
27 Xue-Song Mi, MD, PhD, Department of Ophthalmology, the First Affiliated
28 Hospital of Jinan University, Guangzhou, Guangdong Province, China.

29
30
31 **Phone number:**+86 17665185740

32
33
34 **E-mail address:**kqh211@stu2018.jnu.edu.cn

35
36
37 Wai-kit Ming, MD, PhD, MPH, 1.Department of Public Health and Preventive
38 Medicine, School of Medicine, Jinan University, Guangzhou, China, 2.Li Ka
39 Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

40
41
42
43
44
45 **Phone number:**+86 15625012076

46
47
48 **E-mail address:** 2981365101@qq.com

49
50
51 **Total number of tables plus figures:**6

52
53 **Funding:** The study is supported by the National NSFC (82074169), Hygiene
54 & Health Appropriated Technology and Promoting Project of Guangdong
55 Province (202006130025341204, 201905270933056876) and Project of
56
57
58
59
60

1
2
3
4 Administration of Traditional Chinese Medicine of Guangdong Province of
5
6 China (20202045)
7

8
9 **Conflicts of interest:** The author declares that the publication of this paper has
10
11 no financial support or conflict of interest.
12

13
14 **Key words:** Retinopathy of Prematurity; Anti-VEGF; Refractive Errors; myopia
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Abstract**

2 **Objective:** To determine the effects of the intraocular injection of anti-vascular
3 endothelial growth factor (anti-VEGF) drugs on the refractive status of infants
4 with retinopathy of prematurity(ROP).

5 **Design:** Systematic review and meta-analysis of the refractive status of infants
6 with ROP who receive anti-VEGF drugs.

7 **Data sources:** The PubMed, Web of Science, and EMBASE databases and
8 the ClinicalTrials.gov website were searched up to June 2020.

9 **Eligibility criteria when selecting studies:** We included randomized
10 controlled trials (RCTs) and observational studies that compared refractive
11 errors between anti-VEGF drug and laser therapies.

12 **Data extraction and synthesis:** Data extraction and risk-of-bias assessments
13 were conducted by two independent reviewers. We used a random-effects
14 model to pool outcomes. The outcome measures were the spherical
15 equivalent, axial length (AL), anterior chamber depth (ACD), and lens
16 thickness (LT).

17 **Results:** Thirteen studies involving 1850 eyes were assessed: 914 in the anti-
18 VEGF drug group, and 936 in the control (laser) group. Children who received
19 anti-VEGF drug treatment had less myopia than those who received laser
20 therapy (mean difference =1.80 diopter, 95% confidence interval =: 0.97 to 2.63,
21 $P < 0.0001$, $I^2 = 78\%$). The AL, ACD, and LT did not reach statistical
22 significance difference between the two groups. The current evidence indicates

1
2
3
4 1 that the refractive safety in children with ROP is better for anti-VEGF drug
5
6
7 2 treatment than for laser therapy.

8
9 3 **Conclusions:** This meta-analysis indicates that anti-VEGF drug therapy
10
11
12 4 results in less myopia compared with laser therapy. However, there are
13
14
15 5 relatively few published articles on refractive errors in ROP , and so high-
16
17 6 quality and powerful RCTs are needed in the future.

18
19
20 7 **PROSPERO registration number:** CRD42020160673

21 22 8 **Strengths and limitations of this study**

23
24
25 9 Our meta-analysis adhered to the methodology recommendations of the
26
27
28 10 Cochrane Handbook. We conducted a thorough literature search.

29
30
31 11 The article describes a review protocol that is formally registered on
32
33
34 12 PROSPERO, and the study was conducted and reported on using rigorous
35
36
37 13 methods following the PRISMA statement.

38
39
40 14 We included other parameters that may affect the refractive errors in children
41
42
43 15 with ROP in our meta-analysis, such as ACD, LT, and AL

44
45
46 16 The refractive error measures were from different follow-up time points across
47
48
49 17 studies, this may confound the evaluation of refractive error differences
50
51
52 18 between anti-VEGF and laser

53
54
55 19 Most of the included studies had an observational design, with only two RCTs
56
57
58 20 being included, The inclusion of more RCTs would have allowed more-reliable
59
60 21 conclusions to be drawn.

22 **Introduction**

1 Retinopathy of prematurity (ROP) is a common blinding disease among
2 children in developed countries and is becoming increasingly popular in
3 developing countries.¹ Characterized by retinal ischemia, aberrant
4 angiogenesis, fibrovascular proliferation, and progressive vitreoretinal traction,
5 ROP accounts for 14% and 20% of cases of childhood blindness in the United
6 States and developing countries, respectively.²

7 ROP is a unique retinal vascular proliferative disease occurring in premature
8 and low-birth-weight infants.³ Retinal vascularization normally occurs at around
9 12 weeks of gestation and is completed by 36-40 weeks. This prolonged
10 development period means that the retinal system is immature when infants
11 leave the uterus prematurely. The loss of the maternal interaction environment
12 and exposure to high oxygen levels in premature infants can lead to the
13 cessation of retinal vascularization, damage to the capillary endothelium,
14 hypoxia of the retinal blood vessels, and stimulation of fibrovascular tissue
15 proliferation, and might even finally lead to traction retinal detachment.⁴

16 Laser photocoagulation has previously been the mainstay treatment for ROP.
17 While this intervention is effective and safe, a few defects can remain, such as
18 high myopia, visual field loss, and retinal destruction. An intensive study of ROP
19 found that the levels of vascular endothelial growth factor (VEGF) were
20 markedly elevated in the vitreous of eyes at stage-4 ROP.⁵ In a normally
21 developing retina, VEGF promotes the development of blood vessels from the
22 optic nerve to the periphery, whereas the overexpression of VEGF in preterm

1 infants leads to abnormal vascular proliferation.⁶ This situation has prompted
2 researchers to use anti-VEGF drugs to treat ROP. Many studies have shown
3 that the intravitreal injection of anti-VEGF drugs may be an effective clinical
4 intervention for ROP.^{7,8,9} However, the effects of this intervention are relatively
5 short term, while its long-term complications remain unclear, such as
6 postoperative refractive errors. Kang et al.¹⁰ showed that anti-VEGF drugs do
7 not cause refractive errors after ROP treatment, while Kabatas et al.¹¹ found
8 that effects of the intravitreal injection of anti-VEGF drugs did not differ
9 significantly from those of laser photocoagulation, with both potentially
10 causing refractive errors.

11 The increasing clinical application of anti-VEGF drugs makes it important to
12 know whether these drugs can also cause refractive errors in children with ROP.
13 Hence, the purpose of the present meta-analysis was to determine the effects
14 of anti-VEGF drugs on the refractive status of ROP compared with laser
15 treatment, and to verify their clinical safety. The outcome measures considered
16 in this study were the spherical equivalents (SE), axial length (AL), anterior
17 chamber depth (ACD), and lens thickness (LT).

18 **Methods**

19 Our study is reported on here in accordance with the PRISMA guidelines for
20 meta-analyses.¹² The study has been registered on PROSPERO (registration
21 number CRD42020160673).

1 **Data sources and search strategy.**

2 From their inceptions to January 2020, we searched the PubMed, Web of
3 Science, EMBASE databases, and the ClinicalTrials.gov website using
4 keywords and medical subject headings. Only studies reported on in English
5 were considered for inclusion. We also searched the reference lists of the
6 selected articles to identify any other relevant articles. The search
7 terms included “retinopathy of prematurity,” “prematurity retinopathy,”
8 “retrolental fibroplasia,” “fibroplasia, retrolental,” “ROP,” “anti-VEGF,”
9 “bevacizumab,” “Avastin,” “Lucentis,” “ranibizumab,” “aflibercept,” “anti-
10 vascular endothelial growth factor,” “Mvasi,” and “refractive errors,” “disorders,
11 refractive,” and “ametropias.” The search strategy is detailed in the S1
12 strategy(online supplementary material).

13 **Study selection and eligibility criteria.**

14 Each study was independently screened by two of the authors (Q.H.K.and
15 M.X.S), with discrepancies between them resolved through discussion with the
16 third author (W.M.). The following inclusion criteria were applied : (1) children
17 who had been clearly diagnosed with ROP, (2) subjects in the intervention
18 group had received an intraocular injection of an anti-VEGF drug that can be
19 used in children with ROP,(3) subjects in the control group had received
20 treatment of the eye using a retinal argon or diode laser., (4)the outcome of
21 interest was the refractive status of the treated children with ROP , including

1
2
3
4 1 SE and ocular biometric structural features such as AL, ACD, and LT, and (5)
5
6 2 the study design was a randomized controlled trial(RCT) or an observational
7
8
9 3 study. We excluded children with stage-4 ROP,stage-5 ROP, or other eye
10
11 4 diseases such as congenital cataract or glaucoma prior to treatment.
12
13

14 5 **Data extraction and quality assessment.**

15
16
17
18
19 6 The following information was extracted for the included studies: name of the
20
21 7 first author, publication year, sample size, number of eyes, GA (gestational age),
22
23
24 8 BW (birth weight), follow-up time, type of anti-VEGF drug, dose of anti-VEGF
25
26
27 9 drug , and results data (SE, AL, ACD,and LT). When two anti-VEGF drugs had
28
29
30 10 been applied in a study, we extracted the data separately and compared the
31
32 11 data with the control group.
33
34

35
36 12 We entered the extracted data into an Excel file. Two of the authors (Q.H.K and
37
38 13 M.X.S.) assessed the quality of studies using the Newcastle-Ottawa
39
40 14 Scales(NOS).¹³ The NOS consists of four items for subject selection (maximum
41
42 15 4 points), one item for comparability between groups (maximum 2 points), and
43
44 16 three items for outcome measurement (maximum 3 points). The maximum
45
46 17 score is therefore 9 points, with studies considered to be of moderate quality
47
48 18 having scores of 4–6, and those of high quality having scores of 7–9.¹⁴
49
50
51

52 19 **Statistical analysis.**

53
54
55
56
57 20 The weighted mean differences (WMDs) with 95% confidence intervals (Cis)
58
59
60

1 were calculated for continuous variables. Heterogeneity between the included
2 studies was assessed using the I^2 statistic. I^2 values of 25%-50%, 50%-
3 75%,75%-100% were considered to indicate low, moderate, and high
4 heterogeneity,respectively.¹⁵ Due to the possibility of heterogeneity being
5 present between studies, we used a more conservative version of the random-
6 effects model.

7 A visual funnel plot was used to evaluate publication bias, with an asymmetric
8 plot indicating that publication bias was present. Egger's test was further used
9 to provide accurate assessments of publication bias, with if $P < 0.05$, considered
10 to indicate some degree of publication bias.

11 All statistical analyses were performed using RevMan software (version 5.3,
12 Nordic Cochrane Centre) and Stata software (version 12.0, Stata Corporation).

13 **Results**

14 **Literature search.**

15 The initial literature search identified 121 records. After screening the titles and
16 Abstracts, 31 potentially eligible studies were assessed for inclusion. After
17 reading the full texts ,13 studies were finally included in the present meta-
18 analysis. The study selection process is illustrated in **Figure 1**.

19 The 13 selected studies comprised 2 RCTs^{16,17}, and 11 observational studies^{11,}
20 ¹⁸⁻²⁷. According to the scoring criteria of the NOS, 11 studies were evaluated as
21 being of high quality, while 2 were evaluated as being of moderate quality. The
22 NOS score of the included studies ranged from 6 to 8, with a median of 8. All of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 the articles had been published between 2013 and 2019. The sample sizes in
2 the studies ranged from 12 to 397, with a total of 1850 eyes: 914 in the anti-
3 VEGF drug group and 936 in the control group. The included anti-VEGF drugs
4 were bevacizumab and ranibizumab, with one of these drugs administered in
5 12 studies and 2 drugs administered in 1 study. The dose of anti-VEGF drugs
6 also varied among the included studies, from a minimum of 0.2mg to a
7 maximum of was 1.25mg, with most of the studies using 0.625 mg.

8 After injecting anti-VEGF drugs, children with ROP were followed regularly for
9 more than 6 months, ranging from 9 months to 5 years. SE values were
10 reported for all of the 13 included studies, while ALs, ACDs, and LTs were
11 reported for 4, 3, and 2 studies, respectively. We presented the main
12 information within the included studies in our meta-analysis. (**Table 1**)

Table 1: Main Characteristics of Studies Included in the Meta-analysis

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Harder 2013 ¹⁸	Germany	Anti-VEGF	12/23	25.20 ± 1.60	622.00 ± 153.00	12	bevacizumab	0.375 or 0.625	7
		laser	13/26	25.30± 1.80	717.00 ± 197.00				
Hwang 2015 ¹⁹	American	Anti-VEGF	11/22	NA	668.10 ± 127.30	21.7	bevacizumab	0.625	8
		laser	17/32		701.40 ± 118.80	32.5			
Kabataş 2017 ¹¹ *	Turkey	Anti-VEGF	12/24	26.10 ± 2.27	841.00 ± 235.00	18	bevacizumab	0.625	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kabataş 2017 ¹¹ *	Turkey	Anti-VEGF	6/12	26.00 ± 1.26	840.00 ± 177.00	18	ranibizumab	0.25	8
		laser	36/72	27.70 ± 2.70	1,112.00 ± 362.00				
Kuo 2015 ²⁰	Taiwan	Anti-VEGF	15/15	27.33 ± 2.94	1,079.67 ± 357.48	3 years	bevacizumab	0.5	7
		laser	14/14	27.43± 2.93	1,006.79 ± 327.65	of age			
Kang 2019 ²¹	Korea	Anti-VEGF	12/22	27.40 ± 2.00	983.20 ± 265.60	4 years	bevacizumab	0.625	7
		laser	15/30	34.00 ± 2.90	961.00 ± 286.50	of age	ranibizumab	0.2	
Isaac 2015 ²²	Canada	Anti-VEGF	13/23	25.20 ± 1.40	722.00 ± 131.00	16.00±6.00	bevacizumab	0.625	8
		laser	12/22	25.00 ± 1.10	674.00 ± 175.00	6.00±3.00			
Vujanović2017 ²³	Serbia	Anti-VEGF	21/42	29.00 ± 4.00	1,175.00 ± 425.00	9	bevacizumab	0.625	8
		laser	45/90	30.00 ± 4.00	1,200.00 ± 500.00				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1 (continued)

First author/year	region	Group	patients /eyes(n)	GA(weeks) (mean±SD)	BW(g) (mean±SD)	Follow-up (months)	Type of Anti-VEGF	Anti-VEGF dose(mg)	NOS score
Gunay 2016 ²⁴	Turkey	Anti-VEGF	55/107	27.31 ± 2.18	1005.29 ± 411.19	19.40±6.43	bevacizumab	0.625	8
*		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Gunay 2016 ²⁴	Turkey	Anti-VEGF	22/44	27.95 ± 2.90	1195.90 ± 466.98	18.96±4.79	ranibizumab	0.25	8
*		laser	57/113	28.23 ± 2.50	1119.47 ± 336.96	20.68±6.89			
Chen 2019 ²⁵	Taiwan	Anti-VEGF	13/25	26.46 ± 1.51	862.54 ± 197.65	NA	bevacizumab	0.625	7
		laser	12/22	25.50 ± 1.24	815.83 ± 151.07				
Lee 2018 ²⁶	Taiwan	Anti-VEGF	17/33	26.60 ± 1.60	874.10 ± 228.70	> 48	bevacizumab	0.625	6
		laser	13/24	26.60 ± 2.50	803.10 ± 144.90				
Roohipoor 2018 ²⁷	Iran	Anti-VEGF	NA/397	27.8	1146	> 12	bevacizumab	0.625	8
		laser	NA/190						
Geloneck 2014 ^{16*}	American	Anti-VEGF	56/110	24.3	625	2.5 years of age	bevacizumab	0.625	8
		laser	53/101						
O'Keeffe 2016 ^{17*}	Irish	Anti-VEGF	15/15	25±1.25	780±135	60	bevacizumab	1.25	6
		laser	15/15						

*: RCT, Randomized Controlled Trial; NOS: Newcastle-Ottawa Scale; NA: not applicable; GA: gestational age; BW: birth weight;

* : There are two types of Anti-VEGF drugs included in the literature, so the details are listed separately

1 **Main outcomes**

2 **Spherical equivalent.** The SE values were reported for 914 eyes in the anti-
3 VEGF drug group and 936 eyes in the control group. (**Figure 2**). The SE values
4 were higher in the anti-VEGF drug group than in the control group (MD=1.80
5 diopter, 95% CI=0.97 to 2.63), with a high heterogeneity ($I^2 = 78\%$). The findings
6 of the subgroup analysis of the SE according to type of article are summarized
7 in **Figure 3**. At the same time, according to different types of anti-VEGF
8 drugs(Online supplementary material S2 forest plot) and different follow-up time
9 (Online supplementary material S3 forest plot), we conducted a subgroup
10 analysis.

11 **Axial length.** Three articles^{23, 25, 26} reported the AL, with 251 eyes in the anti-
12 VEGF drug group and 362 eyes in the control group. (**Figure 4**). There was no
13 significant difference in the AL between the groups (MD=-0.04mm, 95%CI: -
14 0.30 to 0.21), and the heterogeneity was low ($I^2 = 30\%$).

15 **Anterior chamber depth.** Three articles^{23, 25, 26} reported the ACD in children
16 with ROP who were or were not taking anti-VEGF drugs. We found no
17 difference in the ACD between the anti-VEGF drug and control
18 groups(MD=0.19mm; 95% CI=-0.14 to 0.52, $I^2 = 85\%$).(Figure 5) There was
19 high heterogeneity($I^2 = 85\%$), but excluding Vujanović's study in the sensitivity
20 analysis resulted in moderate heterogeneity (MD= 0.39mm; 95% CI=-0.06 to
21 0.84, $I^2 = 64\%$).

22 **Lens thickness.** Two articles^{23, 25} reported the LT, which did not differ

1 significantly between the anti-VEGF drug and laser groups (MD=0.06mm; 95%
2 CI: -0.56 to 0.67, P =0.85), and I² was 97%. (online supplementary material: S4
3 forest plot).

4 **Publication bias**

5 Visual examinations of funnel plots constructed using Stata software. and also
6 statistical calculations using in Egger's test did not reveal any publication bias
7 (P =0.401). (online supplementary material S5 funnel plot)

8 **Discussion**

9 The present meta-analysis identified that 13 previous studies have investigated
10 the association between treatments and refractive errors among children with
11 ROP, and analyzed SE, AL, ACD, and LT. A significant difference in SE was
12 found between the two study groups.,This means that anti-VEGF drug
13 treatment reduces the degree of myopia in children with ROP compared with
14 laser treatment, as consistently found in both the comprehensive and subgroup
15 analyses. However, no significant differences were found in the other variables
16 analyzed in this study.

17 Meta-analyses of similar subjects have also been reported.²⁸ The meta-
18 analysis of Tan et al. included 7 articles covering 519 eyes, but this was limited
19 to the anti-VEGF drug bevacizumab. Although the main finding of our meta-
20 analysis was consistent with previous meta-analyses, there are some
21 differences between them. Firstly, our study analyzed the largest amount of
22 data(13 articles covering 1850 eyes) and included some recently published

1 literature, which increased the statistical power of the analyses. Secondly, in
2 addition to the anti-VEGF drug bevacizumab, another anti-VEGF drug that is
3 commonly used in clinical practice was also included (ranibizumab), which
4 makes the present conclusions closer to clinical reality. Thirdly, we added other
5 ocular parameters to investigate how anti-VEGF drug and laser therapies affect
6 refractive errors: ACD, LT, and AL. A previous study showed that these ocular
7 refractive parameters may be related to myopic adults with ROP,²⁹ but no
8 evidence was provided for laser treatment and anti-VEGF drug treatment
9 exerting different effects on the refractive status in children with ROP. We,
10 therefore, analyzed these ocular parameters in laser and anti-VEGF drug
11 groups, with the obtained results providing further evidence that anti-VEGF
12 drug treatment is safe for children with ROP.

13 This meta-analysis of 13 articles synthesized the literature to evaluate the
14 refractive safety of anti-VEGF drugs for children with ROP and has shown that
15 anti-VEGF drug treatment provides better refractive results than does laser
16 treatment. As seen in previous studies, the degree of myopia was reduced more
17 by anti-VEGF drug therapy than by laser treatment in the current study. Most
18 previous studies have quantified refractive errors using SE values, since this
19 parameter is considered the primary measure of such errors, and so we also
20 used this parameter to explore group differences .

21 Kuo et al²⁰ and Issec et al.²² reported that refractive errors did not differ
22 significantly between anti-VEGF drug and laser groups. However, our meta-

1
2
3
4 1 analysis found that anti-VEGF drug therapy reduces refractive errors more than
5
6 2 does laser treatment. Two factors may explain this difference. (1)both of the
7
8
9 3 previous studies included small samples, and(2) a higher proportion of the
10
11 4 children included in the present study had severe ROP. The present findings
12
13
14 5 indicate that anti-VEGF drug therapy may be an alternative to laser therapy for
15
16 6 reducing refractive errors in children with ROP. Our subgroup analysis found
17
18
19 7 that anti-VEGF drug therapy exerted better effects on refractive errors than did
20
21
22 8 laser therapy, based on findings in both RCTs and observational studies.
23
24
25 9 Laser therapy has been considered the first choice of treatment for ROP and
26
27 10 has well-established safety and efficacy. However, this approach results in the
28
29
30 11 retina being permanently cauterized, leading to inadequate vascularization and
31
32
33 12 the risk of visual field loss, high myopia, and cataracts. Regarding refraction, it
34
35
36 13 has also been reported that laser treatment may be a risk factor for refractive
37
38 14 errors in children with ROP.³⁰ Therefore, the impact of future damage to the
39
40
41 15 refractive status that may result from laser treatment needs to be considered
42
43 16 when treating children with ROP, indicating the need to find a treatment method
44
45
46 17 with increased effectiveness and safety. A previous in-depth study of the ROP
47
48
49 18 mechanism found that the intraocular injection of an anti-VEGF drug may be a
50
51 19 good alternative to laser treatment.²² The intraocular injection of anti-VEGF
52
53
54 20 drugs has the advantages of less trauma and pain and involving an easy
55
56 21 procedure, which has resulted in it being increasingly used by a large number
57
58
59 22 of clinicians. This situation makes it essential to clarify the safety regarding
60

1 refractive errors as soon as possible, and the present meta-analysis has
2 provided good evidence for the refractive safety of anti-VEGF drugs.
3 Changes in the biometric structure of the eye—such as in ACD, LT, AL, corneal
4 curvature, and corneal diameter—may be related to increased refractive
5 errors.³¹⁻³³ We, therefore, regard it as essential to consider the above indicators
6 of ocular biometric structure when verifying the refractive status of children with
7 ROP. Although there have been previous meta-analyses of refractive outcomes
8 after treatment of ROP with anti-VEGF drug therapy, none of these meta-
9 analyses explored the relationship between refractive outcomes and the
10 biometric structure of the eye when comparing anti-VEGF drug and laser
11 therapies. Our study found no significant intergroup differences in these
12 parameters. There is also considerable debate about whether anti-VEGF drug
13 treatment of ROP will induce changes in ocular parameters. Lee et al found that
14 AL did not differ among different treatment groups. Gunay et al³⁴ reported that
15 in children who receive anti-VEGF drug therapy, the AL might be related to the
16 development of myopia and is not related to the ACD or LT. The BEAT-ROP
17 believes that anti-VEGF drug treatment may facilitate the continuation of the
18 local growth factor expression and signaling pathways, allowing the anterior
19 segment to develop normally¹⁶. The small number of articles that have reported
20 on the ocular biometric structure makes it difficult to draw definitive conclusions,
21 and so more high-quality RCTs are needed to verify the impact of anti-VEGF
22 drugs on the ocular biometric structure.

1
2
3
4 1 We consider that future research should focus on two main aspects. Firstly,
5
6 2 there is no unified standard for the optimal dose of anti-VEGF drugs to use in
7
8
9 3 the treatment of ROP. Most clinical applications used doses are half of the
10
11 4 adults, but if other doses of anti-VEGF treatment of ROP affect the result, we
12
13
14 5 do not know, so in the future, a clear plan for the dose of anti-VEGF needs to
15
16
17 6 be proposed. Secondly, there is no clear standard for the follow-up time of
18
19
20 7 children with ROP. The conclusions that may be drawn lack credibility if the
21
22 8 follow-up time is too short, and so the most-appropriate follow-up time of
23
24
25 9 children after treatment with anti-VEGF drugs also needs to be determined.

26
27 10 The first strength of our meta-analysis is that it adhered to the methodology
28
29
30 11 recommendations of the Cochrane Handbook, and included conducting a
31
32
33 12 thorough literature search. Secondly, this meta-analysis has a formally
34
35
36 13 registered review protocol on PROSPERO, and our investigations were
37
38
39 14 conducted and reported with rigorous methods following the PRISMA statement.

40
41 15 Thirdly, our meta-analysis included other parameters that may affect the
42
43 16 refractive errors in children with ROP, such as ACD, LT, and AL. The results
44
45
46 17 further strengthen the evidence for the safety of anti-VEGF drugs in children
47
48
49 18 with ROP. However, our study also had certain limitations. First, the refractive
50
51
52 19 error measures were from different follow-up time points across studies, this
53
54
55 20 may confound the evaluation of refractive error differences between anti-VEGF
56
57
58 21 and laser. Second, most of the included studies had an observational design,
59
60 22 with only two RCTs being included, The inclusion of more RCTs would have

1 allowed more-reliable conclusions to be drawn.

2 **Conclusions**

3 In conclusion, the present meta-analysis has shown that anti-VEGF drug
4 therapy reduces the degree of myopia more effectively than does laser
5 treatment. The current evidence indicates that anti-VEGF drug treatment has
6 better refractive safety than laser therapy for children with ROP. Since
7 intraocular injections of angiogenesis factor inhibitors are increasingly being
8 applied, more high-quality RCTs are required.

9 **Footnotes**

10 **Contributors:** Qi-Hang Kong and Xue-Song Mi conceived the idea of the article,
11 Qi-Hang Kong and Xue-Song Mi did the literature search. Qi-Hang Kong, Xue-
12 Song Mi, and Wai-kit Ming undertook the data acquisition and analysis. Qi-
13 Hang Kong carried out the manuscript preparation. Xue-Song Mi and Wai-kit
14 Ming were responsible for the revision of the manuscript. All authors have read
15 and approved the final manuscript.

16 **Funding:** The study is supported by the National NSFC (82074169), Hygiene
17 & Health Appropriated Technology and Promoting Project of Guangdong
18 Province (202006130025341204, 201905270933056876) and Project of
19 Administration of Traditional Chinese Medicine of Guangdong Province of
20 China (20202045)

21 **Conflicts of Interest :** The author declares that the publication of this paper
22 has no financial support or conflict of interest.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Provenance and peer review:** Not commissioned; externally peer-reviewed.

2 **Data sharing statement:** All data analyzed in this study are included in the
3 article and its supplementary files.

Patient and Public Involvement: No patient involved

For peer review only

References

- 1 Chen J, Smith LE. Retinopathy of prematurity. *Angiogenesis*. 2007;10(2):133-40.
- 2 Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of Retinopathy of Prematurity-Use of Anti-VEGF Therapy. *Asia-Pacific journal of ophthalmology (Philadelphia, Pa)*. 2018;7(1):56-62.
- 3 Bashinsky AL. Retinopathy of Prematurity. *North Carolina medical journal*. 2017;78(2):124-8.
- 4 Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. *Lancet (London, England)*. 2013;382(9902):1445-57.
- 5 Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. *The American journal of pathology*. 2000;156(4):1337-44.
- 6 Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. *The Cochrane database of systematic reviews*. 2018;1(1):Cd009734.
- 7 Walz JM, Bemme S, Pielen A, et al. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. *Acta ophthalmologica*. 2016;94(8):e744-e52.
- 8 Tawse KL, Jeng-Miller KW, Bauman CR. Current Practice Patterns for Treatment of Retinopathy of Prematurity. *Ophthalmic surgery, lasers & imaging retina*. 2016;47(5):491-5.
- 9 VanderVeen DK, Melia M, Yang MB, et al. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American

1
2
3
4 Academy of Ophthalmology. *Ophthalmology*. 2017;124(5):619-33.
5

6
7 **10** Kang HG, Choi EY, Byeon SH, et al. Anti-vascular Endothelial Growth Factor Treatment of
8
9 Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. *Korean journal of*
10
11 *ophthalmology: KJO*. 2018;32(6):451-8.
12

13
14 **11** Kabataş EU, Kurtul BE, Altıaylık Özer P, et al. Comparison of Intravitreal Bevacizumab,
15
16 Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of
17
18 Prematurity in Turkish Preterm Children. *Current eye research*. 2017;42(7):1054-8.
19

20
21
22 **12** Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
23
24 meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)*. 2009;339:b2535.
25

26
27 **13** Wells GA SD, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
28
29 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *ohrica*
30
31 http://www.ohrica.com/programs/clinical_epidemiology/oxfordasp; 2000; Accessed 25 Jul 2020.
32
33

34
35 **14** Gu WJ, Hou BL, Kwong JSW, et al. Association between intraoperative hypotension and
36
37 30-day mortality, major adverse cardiac events, and acute kidney injury after non-cardiac
38
39 surgery: A meta-analysis of cohort studies. *International journal of cardiology*. 2018;258:68-73.
40

41
42
43 **15** Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*
44
45 *(Clinical research ed)*. 2003;327(7414):557-60.
46

47
48 **16** Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab
49
50 monotherapy compared with conventional laser treatment: a randomized clinical trial. *JAMA*
51
52 *ophthalmology*. 2014;132(11):1327-33.
53

54
55
56 **17** O'Keefe N, Murphy J, O'Keefe M, et al. Bevacizumab compared with diode laser in stage 3
57
58 posterior retinopathy of prematurity: A 5 year follow up. *Irish medical journal*. 2016;109(2):355.
59
60

1
2
3
4 **18** Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy
5
6 of prematurity: refractive error results. *American journal of ophthalmology*. 2013;155(6):1119-
7
8 24.e1.

9
10
11 **19** Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after Intravitreal Bevacizumab
12
13 versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
14
15 *Ophthalmology*. 2015;122(5):1008-15.

16
17 **20** Kuo HK, Sun IT, Chung MY, et al. Refractive Error in Patients with Retinopathy of
18
19 Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. *Ophthalmologica*
20
21 *Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur*
22
23 *Augenheilkunde*. 2015;234(4):211-7.

24
25 **21** Kang HG, Kim TY, Han J, et al. Refractive Outcomes of 4-Year-old Children after Intravitreal
26
27 Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of
28
29 Prematurity. *Korean journal of ophthalmology: KJO*. 2019;33(3):272-8.

30
31 **22** Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with
32
33 bevacizumab versus laser. *Journal of AAPOS: the official publication of the American*
34
35 *Association for Pediatric Ophthalmology and Strabismus*. 2015;19(2):140-4.

36
37 **23** Vujanovic MS, Stankovic-Babic GL, Oros A, et al. Refractive errors in premature infants with
38
39 retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy.
40
41 *Vojnosanitetski Pregled*. 2017;74(4):323-8.

42
43 **24** Gunay M, Sukgen EA, Celik G, et al. Comparison of Bevacizumab, Ranibizumab, and Laser
44
45 Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. *Current eye*
46
47 *research*. 2017;42(3):462-9.

- 1
2
3
4 **25** Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their
5
6 correlations in school-aged children with retinopathy of prematurity after intravitreal anti-vascular
7
8 endothelial growth factors or laser photocoagulation. *The British journal of ophthalmology*.
9
10 2020;104(5):691-6.
11
12
13
14 **26** Lee YS, See LC, Chang SH, et al. Macular Structures, Optical Components, and Visual
15
16 Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. *American*
17
18 *journal of ophthalmology*. 2018;192:20-30.
19
20
21
22 **27** Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of Intravitreal Bevacizumab
23
24 and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. *Ophthalmology*
25
26 *Retina*. 2018;2(9):942-8.
27
28
29
30 **28** Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for
31
32 retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A
33
34 meta-analysis and systematic review. *PloS one*. 2019;14(12):e0225643.
35
36
37
38 **29** Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity. *American journal of*
39
40 *ophthalmology*. 2008;145(6):1090-4.
41
42
43 **30** Al-Otaibi AG, Aldrees SS, Mousa AA. Long term visual outcomes in laser treated threshold
44
45 retinopathy of prematurity in Central Saudi Arabia. *Saudi journal of ophthalmology : official*
46
47 *journal of the Saudi Ophthalmological Society*. 2012;26(3):299-303.
48
49
50
51 **31** Cook A, White S, Batterbury M, et al. Ocular growth and refractive error development in
52
53 premature infants with or without retinopathy of prematurity. *Investigative ophthalmology &*
54
55 *visual science*. 2008;49(12):5199-207.
56
57
58
59 **32** Chen TC, Tsai TH, Shih YF, et al. Long-term evaluation of refractive status and optical
60

1
2
3
4 components in eyes of children born prematurely. *Investigative ophthalmology & visual science*.

5
6
7 2010;51(12):6140-8.

8
9 **33** Wu WC, Lin RI, Shih CP, et al. Visual acuity, optical components, and macular abnormalities
10
11 in patients with a history of retinopathy of prematurity. *Ophthalmology*. 2012;119(9):1907-16.

12
13
14 **34** Gunay M, Sekeroglu MA, Bardak H, et al. Evaluation of Refractive Errors and Ocular
15
16 Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. *Strabismus*.

17
18
19 2016;24(2):84-8.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 Selection of studies for the meta-analysis

Figure 2 Forest plot of spherical equivalent.

Figure 3 Forest plot of the effect anti-VEGF therapy on spherical equivalent, according to the types of article included

Figure 4 Forest plot of axial length (AL)

Figure 5 Forest plot of anterior chamber depth (ACD).




Figure 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2




Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4




Figure 5

S1 strategy.

Detailed search strategy for PubMed

1. Retinopathy of Prematurity[MeSH]

2. Prematurity Retinopath*[Tiab] OR Retrolental Fibroplasia*[Tiab]OR

Fibroplasia* Retrolental[Tiab]

3.1 OR 2

4. Anti-VEGF[MeSH]

5. Mvasi[Tiab] OR Avastin[Tiab] OR Ranibizumab[Tiab] OR aflibercept[Tiab]

OR Anti-vascular endothelial growth factor[Tiab]

6.4 OR 5

7. Error*,Refractive[MeSH]


8. Error*,Refractive[Tiab] OR Refractive Error*[Tiab]OR

Disorder*,Refractive[Tiab] OR Ametropia[Tiab]


9.7 OR 8

10 3 AND 6 AND 9


S2 forest plot : Forest plot of the effect of different anti-VEGF drugs on spherical equivalent.




S3 forest plot : Forest plot of the influence of different follow-up time on spherical equivalent.



S4 forest plot :Forest plot of lens thickness (LT).



S5 funnel plot: Publication bias was evaluated by the funnel plot.





PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3,4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4,5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7,8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6,7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6(S1 strategy)
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7,8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7,8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8,9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10(Table1)
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13(S2 funnel plot)
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18,19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.